Antibodies that induce immune tolerance, induced lymphocytes, and cell therapeutic agent and therapeutic method using induced lymphocytes
Antibodies inhibiting CD80/CD86 and CD28 interactions are developed to induce immune tolerance in transplant patients, addressing the limitations of current immunosuppressive regimens by reducing cytokine production and preventing transplant rejection.
Patent Information
- Application Number
- JP2024130083
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-06-22
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current immunosuppressive regimens for organ transplantation suppress all immune responses, increasing susceptibility to infections and cancer, and existing methods for inducing antigen-specific immune tolerance in transplant patients are not effective in preventing rejection without activating the immune system.
Development of antibodies that inhibit the interaction between CD80/CD86 and CD28, specifically designed to not activate immune cells like NK cells, thereby reducing cytokine production and inducing immune tolerance without activating the immune system.
The antibodies effectively suppress IFNγ production while maintaining the ability to induce immune tolerance, reducing transplant rejection and other immune-related complications.
Smart Images

Figure 2024160293000002 
Figure 2024160293000003 
Figure 2024160293000004
Abstract
Description
[Technical field]
[0001] The present disclosure relates to a novel technique for immune tolerance. More particularly, the present disclosure relates to an antibody that induces immune tolerance, an induced lymphocyte, and a cell therapy method using the induced lymphocyte. [Background technology]
[0002] Liver transplantation has been widely used as a definitive treatment for patients with end-stage liver failure, with more than 20,000 cases outside Japan and more than 500 cases in Japan each year.
[0003] Transplantation is one of the main treatments of choice for end-stage organ failure, including kidney, heart, liver, and pancreas, and despite significant advances in the treatment of transplant rejection in recent years, the majority of transplants are ultimately rejected without an immunosuppressive regimen. Current immunosuppressive regimens rely on sequential drug therapy, which suppress all immune responses, not just those specifically directed against the transplant, predisposing organ transplant patients to increased susceptibility to infections and cancer.
[0004] Regenerative medicine is also attracting attention, but even if induced pluripotent stem cells (iPS cells) are used, immune rejection reactions may still occur unless the cells are of autologous origin, so immune tolerance technology is attracting attention.
[0005] One technique for inducing this immune tolerance is the induction of antigen-specific immune responses (anergy) in T cells. Specifically, a technique has been reported in which an antibody that inhibits the interaction between CD80 / CD86 on antigen-presenting cells and CD28 on unactivated (naive) T cells is directly administered to an organ transplant patient to induce donor antigen-specific anergy in vivo (Patent Document 1), and a technique has been reported in which donor antigen-specific anergy cells are induced ex vivo by co-culturing recipient cells and irradiated donor cells in the presence of the same antibody, and then the cells are returned to the recipient (Patent Document 2, Patent Document 3, and Non-Patent Documents 1-3). [Prior art documents] [Patent documents]
[0006] [Patent Document 1] Special Publication No. 2002-504120 [Patent Document 2] Special Publication No. 2007-131598 [Patent Document 3] Special Publication No. 2016-520081 [Non-patent literature]
[0007] [Non-Patent Document 1] Satoru Todo et al.Hepatology, 64(vol.2), 632-643 (2016) [Non-Patent Document 2] Teraoka S, Koyama I, Bashuda H, Uchida K, Tonsho M, et al. (2017) J Transplant Res 2(1) p1-8 [Non-Patent Document 3] Bashuda H et al., J. Clin. Invest. 115:1896-1902 (2005). Summary of the Invention [Means for solving the problem]
[0008] The present inventors have attempted to induce an immune response (anergy) using an antibody having a certain human Fc region that inhibits the interaction between CD80 / CD86 and CD28, and have found that the antibody binds to cells involved in the immune system, such as macrophages, neutrophils, and natural killer (NK) cells, thereby activating these cells and inducing the release of humoral factors such as interleukins and interferons (IFNs) that control immune responses. The present inventors have newly discovered that since the release of these humoral factors induces undesirable activation of the immune system, which is the opposite of immune tolerance, the effect of immune tolerance can be improved or the attenuation of the effect of immune tolerance can be suppressed by adjusting the induction of an immune response (anergy) using an antibody having a human Fc region that does not bind to these cells. Thus, the present inventors provide an antibody having a structure that has the characteristic of improving the effect of immune tolerance or not attenuating the effect of immune tolerance.
[0009] Thus, the present disclosure provides: (1) An antibody or a variant thereof that inhibits the interaction between CD80 and / or CD86 expressed on the cell surface of a certain cell and CD28 expressed on the cell surface of another cell, and that does not substantially induce cytokine production due to immune activation. (2) The antibody or its modified form described in the above item, wherein the cytokine comprises interferon γ. (3) An antibody or a modified version thereof according to any of the preceding items, which is a chimeric antibody. (4) The antibody or modified antibody according to any one of the preceding items, wherein the subclass of the antibody is IgG1. (5) The antibody or variant thereof according to any of the preceding items, which has a heavy chain having the amino acid sequence set forth in SEQ ID NO: 38 or 42, and a light chain having the amino acid sequence set forth in SEQ ID NO: 40 or 44. (6)(a) a VH comprising a CDRH1 having the amino acid sequence set forth in SEQ ID NO: 53, a CDRH2 having the amino acid sequence set forth in SEQ ID NO: 54, and a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 55, and a VL comprising a CDRL1 having the amino acid sequence set forth in SEQ ID NO: 56, a CDRL2 having the amino acid sequence set forth in SEQ ID NO: 57, and a CDRL3 having the amino acid sequence set forth in SEQ ID NO: 58; or (b) a VH comprising a CDRH1 having the amino acid sequence set forth in SEQ ID NO: 59, a CDRH2 having the amino acid sequence set forth in SEQ ID NO: 60, and a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 61, and a VL comprising a CDRL1 having the amino acid sequence set forth in SEQ ID NO: 62, a CDRL2 having the amino acid sequence set forth in SEQ ID NO: 63, and a CDRL3 having the amino acid sequence set forth in SEQ ID NO: 64. The antibody or variant thereof according to any one of the above items. (7) (a) a VH having the amino acid sequence set forth in SEQ ID NO: 46 or a modified sequence thereof and a VL having the amino acid sequence set forth in SEQ ID NO: 48 or a modified sequence thereof; or (b) a VH having the amino acid sequence set forth in SEQ ID NO: 50 or a modified sequence thereof, and a VL having the amino acid sequence set forth in SEQ ID NO: 52 or a modified sequence thereof The antibody or variant thereof according to any one of the above items. (8) The antibody or its variant according to any one of the preceding items, wherein the Fc portion of the antibody does not substantially induce cytokine production due to immune activation. (9) The antibody or its variant according to any one of the preceding items, wherein the subclass of the antibody is IgG2 or IgG4. (10) The antibody or its variant according to any one of the preceding items, wherein the subclass of the antibody is IgG4. (11) The antibody or its variant according to any one of the preceding items, wherein the variant of the antibody lacks the Fc portion of the antibody. (12) The antibody or its variant according to any one of the preceding items, wherein the variant is a Fab antibody, an F(ab')2 antibody, an Fab' antibody, an Fv antibody or an scFv antibody. (13) The antibody or its modified form according to any one of the preceding items, which has the ability to induce immune tolerance. (14) The antibody or variant thereof according to any of the preceding items, wherein the cell expressing CD80 and / or CD86 is an antigen-presenting cell, and the other cell expressing CD28 is a T cell. (15) The antibody or its variant according to any one of the preceding items, wherein the antibody or its variant is an antagonistic anti-CD80 antibody, an antagonistic anti-CD86 antibody, an antagonistic anti-CD28 antibody, or an antagonistic bispecific antibody against CD80 and CD86, or a variant thereof. (16) The antibody or variant thereof according to any of the preceding items, which is a humanized antibody or a human antibody, or a variant thereof. (17) The antibody or modified antibody according to any one of the preceding items, which comprises an IgG2 or IgG4 Fc portion of a human antibody. (18) The antibody or modified antibody according to any one of the preceding items, which contains an IgG4 Fc portion of a human antibody. (19)(a) a VH comprising a CDRH1 having the amino acid sequence set forth in SEQ ID NO: 25, a CDRH2 having the amino acid sequence set forth in SEQ ID NO: 26, and a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 27, and a VL comprising a CDRL1 having the amino acid sequence set forth in SEQ ID NO: 28, a CDRL2 having the amino acid sequence set forth in SEQ ID NO: 29, and a CDRL3 having the amino acid sequence set forth in SEQ ID NO: 30; or (b) a VH comprising a CDRH1 having the amino acid sequence set forth in SEQ ID NO: 31, a CDRH2 having the amino acid sequence set forth in SEQ ID NO: 32, and a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 33, and a VL comprising a CDRL1 having the amino acid sequence set forth in SEQ ID NO: 34, a CDRL2 having the amino acid sequence set forth in SEQ ID NO: 35, and a CDRL3 having the amino acid sequence set forth in SEQ ID NO: 36. The antibody or variant thereof according to any one of the above items. (20) (a) a VH having the amino acid sequence set forth in SEQ ID NO: 18 or a modified sequence thereof and a VL having the amino acid sequence set forth in SEQ ID NO: 20 or a modified sequence thereof (b) a VH having the amino acid sequence set forth in SEQ ID NO: 22 or a modified sequence thereof, and a VL having the amino acid sequence set forth in SEQ ID NO: 24 or a modified sequence thereof The antibody or variant thereof according to any one of the above items. (21) A nucleic acid molecule encoding the amino acid sequence or a part of the antibody or variant thereof according to any of the preceding items. (22)(a) a polynucleotide encoding a VH having a nucleotide sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 45, and a polynucleotide encoding a VL having a nucleotide sequence set forth in SEQ ID NO: 19 or SEQ ID NO: 47; or (b) a polynucleotide encoding a VH having the nucleotide sequence set forth in SEQ ID NO: 21 or SEQ ID NO: 49, and a polynucleotide encoding a VL having the nucleotide sequence set forth in SEQ ID NO: 23 or SEQ ID NO: 51. A nucleic acid molecule according to any one of the preceding items, comprising: (23) A vector having a nucleic acid molecule according to any one of the above items. (24) A cell comprising the nucleic acid molecule according to any one of the preceding items or the vector according to item 23. (25) A method for producing the antibody or variant thereof according to any of the above items, comprising culturing any of the cells according to the above items. (26) A cell in which immune tolerance has been induced by any of the above-mentioned antibodies or modified antibodies thereof. (27) The cell according to any of the preceding items, wherein the immune tolerance is induced by mixing the antibody or its modified form, a cell derived from a subject, and an antigen not derived from the subject or a substance containing the antigen. (28) A composition for producing cells in which immune tolerance has been induced, comprising at least one of the antibodies or variants thereof described in any of the preceding items. (29) The composition according to any of the preceding items, comprising an antagonistic anti-CD80 antibody, an antagonistic anti-CD86 antibody, an antagonistic anti-CD28 antibody, or an antagonistic bispecific antibody against CD80 and CD86, or a variant thereof, or any combination thereof. (30) A method for producing cells for treating or preventing a disease, disorder, or condition caused by an antigen not derived from a subject, comprising the step of mixing the antibody or modified version thereof according to any of the preceding items, cells derived from a subject, and an antigen not derived from the subject or a substance containing the antigen. (31) The method according to any of the preceding items, wherein the disease, disorder or condition is selected from the group consisting of transplant immune rejection, allergy, autoimmune disease, graft-versus-host disease, and immune rejection caused by transplantation of iPS cells or ES cells and cells, tissues or organs derived therefrom. (32) The method according to any of the preceding items, wherein the antigen-containing object is a cell. (33) A cell produced by the method according to any one of the above items. (34) The cell according to any one of the preceding items, comprising a T cell. (35) A cell therapeutic agent comprising a cell in which immune tolerance has been induced with the antibody or its modified form described in any of the above items, a cell produced by the method described in any of the above items, or the cell described in any of the above items. (36) A composition for treating or preventing a disease, disorder, or condition caused by an antigen not derived from a subject, comprising a cell in which immune tolerance has been induced with the antibody or a variant thereof described in any of the above items, a cell produced by the method described in any of the above items, or the cell described in any of the above items. (37) The composition according to any of the preceding items, wherein the disease, disorder or condition is selected from the group consisting of transplant immune rejection, allergy, autoimmune disease, graft-versus-host disease, and immune rejection caused by transplantation of iPS cells or ES cells and cells, tissues or organs derived from these cells. (38) The composition according to any of the preceding items, wherein the immune rejection is characterized in that the organ to be transplanted is a kidney, liver, heart, skin, lung, pancreas, esophagus, stomach, small intestine, large intestine, nerve, blood, blood cells including immune system cells, bone, cartilage, blood vessels, cornea, eyeball, or bone marrow. (39) A method for treating or preventing in a subject a disease, disorder, or condition caused by an antigen not derived from the subject, comprising the step of administering to the subject an effective amount of a cell in which immune tolerance has been induced with the antibody or modified version thereof described in any of the above items, a cell produced by the method described in any of the above items, or a cell described in any of the above items. (40) The method according to any of the preceding items, wherein the disease, disorder or condition is selected from the group consisting of transplant immune rejection, allergy, autoimmune disease, graft-versus-host disease, and immune rejection caused by transplantation of iPS cells or ES cells and cells, tissues or organs derived therefrom. (41) The method according to any one of the preceding items, wherein the immune rejection is caused by the transplanted organ being a kidney, liver, heart, skin, lung, pancreas, esophagus, stomach, small intestine, large intestine, nerve, blood, blood cells including immune system cells, bone, cartilage, blood vessel, cornea, eyeball, or bone marrow. (39A) Use of a cell in which immune tolerance has been induced with the antibody or variant thereof described in any of the preceding items, a cell produced by the method described in any of the preceding items, or a cell described in any of the preceding items, for producing a medicament for treating or preventing a disease, disorder, or condition in a subject caused by an antigen not derived from the subject. (40A) The use according to any of the preceding items, wherein the disease, disorder or condition is selected from the group consisting of transplant immune rejection, allergy, autoimmune disease, graft-versus-host disease, and immune rejection caused by transplantation of iPS cells or ES cells and cells, tissues or organs derived from these cells. (41A) The use according to any of the preceding items, wherein the immune rejection is caused by transplantation of a kidney, liver, heart, skin, lung, pancreas, esophagus, stomach, small intestine, large intestine, nerve, blood, blood cells including immune system cells, bone, cartilage, blood vessel, cornea, eyeball, or bone marrow. (39B) A cell in which immune tolerance has been induced with the antibody or variant thereof described in any of the preceding items, a cell produced by the method described in any of the preceding items, or the cell described in any of the preceding items, for producing a medicament for treating or preventing a disease, disorder, or condition in a subject caused by an antigen not derived from the subject. (40B) The cell according to any of the preceding items, wherein the disease, disorder or condition is selected from the group consisting of transplant immune rejection, allergy, autoimmune disease, graft-versus-host disease, and immune rejection caused by transplantation of iPS cells or ES cells and cells, tissues or organs derived therefrom. (41B) The cell according to any of the preceding items, characterized in that the immune rejection is caused by the transplanted organ being a kidney, liver, heart, skin, lung, pancreas, esophagus, stomach, small intestine, large intestine, nerve, blood, blood cells including immune system cells, bone, cartilage, blood vessel, cornea, eyeball, or bone marrow. The present disclosure also provides the following. (A1) An antibody that inhibits the interaction between CD80 and / or CD86 expressed on the cell surface of a certain cell and CD28 expressed on the cell surface of another cell, and does not substantially induce cytokine production due to immune activation. (A2) The antibody described in (A1), wherein the cytokine includes interferon gamma. (A3) The antibody according to (A1) or (A2), wherein the Fc portion of the antibody does not substantially induce cytokine production due to immune activation. (A4) The antibody according to any one of (A1) to (A3), wherein the subclass of the antibody is IgG2 or IgG4. (A5) The antibody according to (A4), wherein the subclass of the antibody is IgG4. (A6) The antibody described in (A1) or (A2), wherein the antibody lacks an Fc portion. (A7) The antibody according to (A6), which is a Fab antibody, a F(ab')2 antibody, a Fab' antibody, an Fv antibody or an scFv antibody. (A8) The antibody according to any one of (A1) to (A7), which has the ability to induce immune tolerance. (A9) The antibody described in any one of (A1) to (A8), wherein the cell expressing CD80 and / or CD86 is an antigen-presenting cell, and the other cell expressing CD28 is a T cell. (A10) The antibody according to any one of (A1) to (A9), wherein the antibody is an antagonistic anti-CD80 antibody, an antagonistic anti-CD86 antibody, an antagonistic anti-CD28 antibody, or an antagonistic bispecific antibody against CD80 and CD86. (A11) The antibody according to any one of (A1) to (A10), which is a chimeric antibody, a humanized antibody or a human antibody. (A12) The antibody according to any one of (A1) to (A11), which comprises an Fc portion of a human antibody IgG2 or IgG4. (A13) The antibody according to any one of (A1) to (A12), which comprises an Fc portion of IgG4 of a human antibody. (A14) (a) a VH comprising a CDRH1 having the amino acid sequence set forth in SEQ ID NO: 25, a CDRH2 having the amino acid sequence set forth in SEQ ID NO: 26, and a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 27, and a VL comprising a CDRL1 having the amino acid sequence set forth in SEQ ID NO: 28, a CDRL2 having the amino acid sequence set forth in SEQ ID NO: 29, and a CDRL3 having the amino acid sequence set forth in SEQ ID NO: 30; or (b) a VH comprising a CDRH1 having the amino acid sequence set forth in SEQ ID NO: 31, a CDRH2 having the amino acid sequence set forth in SEQ ID NO: 32, and a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 33, and a VL comprising a CDRL1 having the amino acid sequence set forth in SEQ ID NO: 34, a CDRL2 having the amino acid sequence set forth in SEQ ID NO: 35, and a CDRL3 having the amino acid sequence set forth in SEQ ID NO: 36. The antibody according to any one of (A1) to (A13), comprising: (A15) (a) a VH having the amino acid sequence set forth in SEQ ID NO: 18 or a modified sequence thereof and a VL having the amino acid sequence set forth in SEQ ID NO: 20 or a modified sequence thereof (b) a VH having the amino acid sequence set forth in SEQ ID NO: 22 or a modified sequence thereof, and a VL having the amino acid sequence set forth in SEQ ID NO: 24 or a modified sequence thereof The antibody according to (A14), (A16) A nucleic acid molecule encoding the amino acid sequence of the antibody according to any one of (A1) to (A15) or a part thereof. (A17) (a) a polynucleotide encoding a VH having the nucleotide sequence set forth in SEQ ID NO: 17, and a polynucleotide encoding a VL having the nucleotide sequence set forth in SEQ ID NO: 19; or (b) a polynucleotide encoding a VH having the nucleotide sequence set forth in SEQ ID NO: 21, and a polynucleotide encoding a VL having the nucleotide sequence set forth in SEQ ID NO: 23. The nucleic acid molecule according to (A16), (A18) A vector having the nucleic acid molecule according to (A16) or (A17). (A19) A cell comprising the nucleic acid molecule according to (A16) or (A17) or the vector according to (A18). (A20) A method for producing the antibody according to any one of (A1) to (A15), comprising culturing the cell of (A19). (A21) A cell in which immune tolerance has been induced by the antibody according to any one of (A1) to (A15). (A22) The cell according to (A21), in which the immune tolerance is induced by mixing the antibody, a cell derived from a subject, and an antigen not derived from the subject or a substance containing the antigen. (A23) A composition for producing a cell in which immune tolerance has been induced, comprising at least one of the antibodies according to any one of (A1) to (A15). (A24) The composition according to (A23), comprising an antagonistic anti-CD80 antibody, an antagonistic anti-CD86 antibody, an antagonistic anti-CD28 antibody, or an antagonistic bispecific antibody against CD80 and CD86, or any combination thereof. (A25) A method for producing cells for treating or preventing a disease, disorder, or condition caused by an antigen not derived from the subject, comprising a step of mixing the antibody according to any one of (A1) to (A15), cells derived from a subject, and an antigen not derived from the subject or a substance containing the antigen. (A26) The method according to (A25), wherein the disease, disorder or condition is selected from the group consisting of transplant immune rejection, allergy, autoimmune disease, graft-versus-host disease, and immune rejection caused by transplantation of iPS cells or ES cells and cells, tissues or organs derived therefrom. (A27) The method according to (A25) or (A26), wherein the antigen-containing object is a cell. (A28) A cell produced by the method according to any one of (A25) to (A27). (A29) The cell according to (A28), which comprises a T cell. (A30) A cell therapeutic agent comprising a cell in which immune tolerance has been induced by the antibody according to any one of (A1) to (A15), a cell produced by the method according to (A25) or (A26), or the cell according to (A21), (A22), (A28) or (A29). (A31) A composition for treating or preventing a disease, disorder, or condition caused by an antigen not derived from a subject, comprising a cell in which immune tolerance has been induced with the antibody according to any one of (A1) to (A15), a cell produced by the method according to (A25) or (A26), or a cell according to (A21), (A22), (A28) or (A29). (A32) The composition according to (A31), wherein the disease, disorder or condition is selected from the group consisting of transplant immune rejection, allergy, autoimmune disease, graft-versus-host disease, and immune rejection caused by transplantation of iPS cells or ES cells and cells, tissues or organs derived from these cells. (A33) The composition according to (A32), wherein the immune rejection is characterized in that the organ to be transplanted is a kidney, liver, heart, skin, lung, pancreas, esophagus, stomach, small intestine, large intestine, nerve, blood, blood cells including immune system cells, bone, cartilage, blood vessel, cornea, eyeball or bone marrow. (A34) A method for treating or preventing in a subject a disease, disorder or condition caused by an antigen not derived from the subject, comprising the step of administering to the subject an effective amount of a cell in which immune tolerance has been induced with the antibody according to any one of (A1) to (A15), a cell produced by the method according to (A23) or (A24), or a cell according to (A21), (A22), (A28) or (A29). (A35) The method according to (A34), wherein the disease, disorder or condition is selected from the group consisting of transplant immune rejection, allergy, autoimmune disease, graft-versus-host disease, and immune rejection caused by transplantation of iPS cells or ES cells and cells, tissues or organs derived from these cells. (A36) The method according to (A35), wherein the immune rejection is caused by transplantation of a kidney, liver, heart, skin, lung, pancreas, esophagus, stomach, small intestine, large intestine, nerve, blood, blood cells including immune system cells, bone, cartilage, blood vessel, cornea, eyeball or bone marrow.
[0010] The present disclosure further relates to the following inventions: (B1) An antibody having a human Fc region, capable of inhibiting the interaction between CD80 or CD86 expressed on a cell surface and CD28 expressed on the surface of other cells, and not promoting cytokine production by human PBMCs. (B2) The antibody described in (B1), which is capable of inhibiting the interaction between CD80 or CD86 expressed on the surface of an antigen-presenting cell and CD28 expressed on the surface of a T cell. (B3) The antibody according to (B1) or (B2), which is capable of inducing immune tolerance to an antigen by contacting PBMCs with the antigen or cells having the antigen on their surface. (B4) The antibody according to any one of (B1) to (B3), wherein the cytokine is IFNγ. (B5) The antibody according to any one of (B1) to (B4), which is an anti-CD80 antibody or an anti-CD86 antibody. (B6) The antibody according to any one of (B1) to (B5), which is a chimeric antibody, a humanized antibody, or a human antibody. (B7) The antibody according to any one of (B1) to (B6), which is a monoclonal antibody. (B8) The antibody according to any one of (B1) to (B7), whose subclass is IgG2 or IgG4. (B8A) The antibody according to any one of (B1) to (B7), whose subclass is IgG1. (B8B) The antibody described in (B8A), having a heavy chain having an amino acid sequence described in one of SEQ ID NOs: 38 and 42. (B8C) having a heavy chain having the amino acid sequence set forth in SEQ ID NO: 38 and a light chain having the amino acid sequence set forth in SEQ ID NO: 40; or The antibody described in (B8B), having a heavy chain having the amino acid sequence set forth in SEQ ID NO: 42 and a light chain having the amino acid sequence set forth in SEQ ID NO: 44. (B8D) The antibody described in any one of (B1) to (B7), (B8A) to (B8C), having a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 55 or SEQ ID NO: 61. (B8E) The antibody according to (B8D), (Bi) an antibody having a CDRH1 having the amino acid sequence set forth in SEQ ID NO: 53, a CDRH2 having the amino acid sequence set forth in SEQ ID NO: 54, and a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 55; or (Bii) An antibody having a CDRH1 having the amino acid sequence set forth in SEQ ID NO: 59, a CDRH2 having the amino acid sequence set forth in SEQ ID NO: 60, and a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 61. (B8F) An antibody according to (Bi) of (B8E), which has CDRL1 having the amino acid sequence set forth in SEQ ID NO: 56, CDRL2 having the amino acid sequence set forth in SEQ ID NO: 57, and CDRL3 having the amino acid sequence set forth in SEQ ID NO: 58; or An antibody described in (Bii) of (B8E), having CDRL1 having the amino acid sequence set forth in SEQ ID NO: 62, CDRL2 having the amino acid sequence set forth in SEQ ID NO: 63, and CDRL3 having the amino acid sequence set forth in SEQ ID NO: 64. (B8G) The antibody described in (B8D) having a heavy chain variable region (VH) having the amino acid sequence described in SEQ ID NO: 46 or SEQ ID NO: 50. (B8H) An antibody described in (B8G), having a VH having the amino acid sequence set forth in SEQ ID NO: 46 and a light chain variable region (VL) having the amino acid sequence set forth in SEQ ID NO: 48, or having a VH having the amino acid sequence set forth in SEQ ID NO: 50 and a VL having the amino acid sequence set forth in SEQ ID NO: 52. (B8I) An antibody described in (B8G) having a heavy chain having an amino acid sequence set forth in one of SEQ ID NOs: 38 and 42. (B8J) having a heavy chain having the amino acid sequence set forth in SEQ ID NO: 38 and a light chain having the amino acid sequence set forth in SEQ ID NO: 40; or The antibody according to (B8I), having a heavy chain having the amino acid sequence set forth in SEQ ID NO: 42 and a light chain having the amino acid sequence set forth in SEQ ID NO: 44. (B9) The antibody according to any one of (B1) to (B8), having a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 27 or SEQ ID NO: 33. (B10) The antibody according to (B9), (Bi) an antibody having a CDRH1 having the amino acid sequence set forth in SEQ ID NO: 25, a CDRH2 having the amino acid sequence set forth in SEQ ID NO: 26, and a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 27; or (Bii) An antibody having a CDRH1 having the amino acid sequence set forth in SEQ ID NO: 31, a CDRH2 having the amino acid sequence set forth in SEQ ID NO: 32, and a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 33. (B11) The antibody according to (Bi) of (B10), which has CDRL1 having the amino acid sequence set forth in SEQ ID NO: 28, CDRL2 having the amino acid sequence set forth in SEQ ID NO: 29, and CDRL3 having the amino acid sequence set forth in SEQ ID NO: 30; or An antibody according to (Bii) of (B10), having CDRL1 having the amino acid sequence set forth in SEQ ID NO: 34, CDRL2 having the amino acid sequence set forth in SEQ ID NO: 35, and CDRL3 having the amino acid sequence set forth in SEQ ID NO: 36. (B12) The antibody described in (B9), having a heavy chain variable region (VH) having the amino acid sequence described in SEQ ID NO: 18 or SEQ ID NO: 22. (B13) The antibody described in (B12), having a VH having the amino acid sequence set forth in SEQ ID NO: 18 and a light chain variable region (VL) having the amino acid sequence set forth in SEQ ID NO: 20, or having a VH having the amino acid sequence set forth in SEQ ID NO: 22 and a VL having the amino acid sequence set forth in SEQ ID NO: 24. (B14) The antibody described in (B12), having a heavy chain having an amino acid sequence set forth in one of SEQ ID NOs: 2, 6, 10, and 14. (B15) A heavy chain having the amino acid sequence set forth in SEQ ID NO: 2 and a light chain having the amino acid sequence set forth in SEQ ID NO: 4, a heavy chain having the amino acid sequence set forth in SEQ ID NO:6 and a light chain having the amino acid sequence set forth in SEQ ID NO:8; a heavy chain having the amino acid sequence set forth in SEQ ID NO: 10 and a light chain having the amino acid sequence set forth in SEQ ID NO: 12; or The antibody described in (B14), having a heavy chain having the amino acid sequence described in SEQ ID NO: 14 and a light chain having the amino acid sequence described in SEQ ID NO: 16. (B16) A medical composition comprising the antibody according to any one of (B1) to (B15). (B17) The medical composition according to (B16), which comprises an anti-CD80 antibody or an anti-CD86 antibody. (B18) The medical composition according to (B16) or (B17), which is used for inducing immune tolerance. (B19) The medical composition according to (B18), which is used for inducing immune tolerance in cells collected from a patient undergoing organ transplantation. (B20) The medical composition according to (B19) or (B20), wherein the organ to be transplanted is the heart, kidney or liver. (B21) The medical composition according to (B18), which is used for inducing immune tolerance in a patient with an autoimmune disease or an allergic disease. (B22) A nucleic acid molecule encoding the amino acid sequence of the antibody according to any one of (B12) to (B15). (B23) The nucleic acid molecule according to (B22), comprising a polynucleotide encoding a VH having a nucleotide sequence selected from any one of SEQ ID NOs: 1, 5, 9, and 13, and a polynucleotide encoding a VL having a nucleotide sequence selected from any one of SEQ ID NOs: 3, 7, 11, and 15. (B24) A vector having the nucleic acid molecule according to (B22) or (B23). (B25) A host cell carrying the vector according to (B24). (B26) A method for producing the antibody according to any one of (B1) to (B15), comprising culturing the host cell of (B25). (B27) A method for inducing immune tolerance in PBMCs to an antigen, the method comprising contacting PBMCs with the antibody according to any one of (B1) to (B15), an antigen to which immune tolerance is to be induced or cells having the antigen on their surface. (B28) The method for inducing according to (B27), characterized in that it is carried out ex vivo. (B29) The method according to (B27) or (B28), wherein the PBMCs are cells collected from a patient undergoing organ transplantation. (B30) The method according to (B27) or (B28), wherein the PBMCs are cells collected from a patient with an autoimmune disease or an allergic disease. (B31) PBMCs in which immune tolerance has been induced by the method according to any one of (B27) to (B30). (B32) A cell therapy agent comprising the PBMC according to (B30) as an active ingredient. (B33) The cell therapeutic agent according to (B32) for suppressing rejection in organ transplantation. (B34) The cell therapy agent according to (B33), characterized in that the organ to be transplanted is a kidney, liver, heart, skin, lung, pancreas, esophagus, stomach, small intestine, large intestine, nerve, blood, blood cells including immune system cells, bone, cartilage, blood vessels, cornea, eyeball or bone marrow. (B35) The cell therapeutic agent according to (B32) for treating an autoimmune disease or an allergic disease. (B36) A method for suppressing rejection in organ transplantation, comprising administering the antibody according to any one of (B1) to (B15) to a patient receiving an organ transplant. (B37) The method according to (B36), wherein the organ to be transplanted is a kidney, a liver, a heart, skin, a lung, a pancreas, an esophagus, a stomach, a small intestine, a large intestine, a nerve, blood, a blood cell including an immune system cell, a bone, a cartilage, a blood vessel, a cornea, an eyeball or a bone marrow. (B37) A method for treating an autoimmune disease or an allergic disease, comprising administering the antibody according to any one of (B1) to (B15) to a patient suffering from an autoimmune disease or an allergic disease. (B38) A method for suppressing rejection in organ transplantation, comprising administering the cellular therapeutic agent according to any one of (B32) to (B34) to a patient undergoing organ transplantation. (B39) A method for treating an autoimmune disease or an allergic disease, comprising administering the cell therapeutic agent of (B32) or (B35) to a patient suffering from an autoimmune disease or an allergic disease. (B40) The method according to any one of (B27) to (B30), further comprising administering to a patient PBMC in which immune tolerance has been induced. (B41) The method according to (B40), which comprises administering PBMCs derived from a patient in which immune tolerance to the organ to be transplanted has been induced to a patient receiving an organ transplant. (B42) The method according to (B40), which comprises administering PBMCs derived from a patient in which immune tolerance has been induced against an antigen causing the autoimmune disease or allergic disease to a patient suffering from an autoimmune disease or an allergic disease.
[0011] It is contemplated that the present disclosure may provide one or more of the above features in combinations other than those specifically described. Still further embodiments and advantages of the present disclosure will be recognized by those skilled in the art upon reading and understanding the following detailed description, if necessary. Effect of the Invention
[0012] The antibodies of the present disclosure suppress IFNγ production while maintaining the ability to induce immune tolerance. In particular, the antibodies of the present disclosure that belong to the subclass IgG2 or IgG4 can produce cells that induce immune tolerance without producing IFNγ. [Brief description of the drawings]
[0013] [Figure 1] The results of mixed lymphocyte reaction (3H-thymidine incorporation) in the presence of anti-human CD80 and anti-CD86 antibodies (IgG1) are shown. Naive: no donor added, no antibody added. Allo: donor added, no antibody added. 10, 1, 0, 1 are the concentrations (μg / ml) of each antibody added. The vertical axis shows 3H-thymidine incorporation relative to no antibody added (Allo). [Diagram 2] The results of mixed lymphocyte reaction (IFNγ production) in the presence of anti-human CD80 and anti-CD86 antibodies (IgG1) are shown. The vertical axis indicates the concentration (pg / ml) in the medium. [Diagram 3] The results of mixed lymphocyte reaction (3H-thymidine incorporation) in the presence of anti-human CD80 and anti-CD86 antibodies (IgG1) are shown. The vertical axis indicates 3H-thymidine incorporation relative to the level without addition of antibodies (Allo). [Figure 4]The results of mixed lymphocyte reaction (IFNγ production) in the presence of anti-human CD80 and anti-CD86 antibodies (IgG1) are shown. Upper row: with donor stimulation, lower row: without donor stimulation. * indicates 50,000 pg / mL or more. The vertical axis indicates the concentration in the medium (pg / ml). [Diagram 5] The results of mixed lymphocyte reaction (3H-thymidine incorporation) in the presence of anti-CD80 and anti-CD86 antibodies (IgG2, IgG4) are shown. The vertical axis shows 3H-thymidine incorporation relative to the control without antibody (Allo). 10, 3, and 1 are the concentrations (μg / ml) of each antibody added. [Figure 6] The results of mixed lymphocyte reaction (IFNγ production) in the presence of anti-CD80 and anti-CD86 antibodies (IgG1, IgG2, IgG4) are shown. The vertical axis indicates the concentration (pg / ml) in the medium. [Figure 7] The results of the mixed lymphocyte reaction (3H-thymidine incorporation) when cells were added in the presence of anti-CD80 and anti-CD86 antibodies (IgG1, IgG2, IgG4) are shown. The vertical axis indicates 3H-thymidine incorporation based on the case without antibody addition (Allo). 1 / 2, 1 / 4, and 1 / 8 are the mixing ratios of cells obtained in the presence of anti-CD80 and anti-CD86 antibodies (IgG1, IgG2, IgG4) to naive responder cells. [Figure 8] 1 shows the results of mixed lymphocyte reaction (IFNγ production) in the presence of chimeric anti-CD80 antibody and chimeric anti-CD86 antibody. The vertical axis shows the concentration in the medium (pg / ml). [Figure 9] The results of mixed lymphocyte reaction (3H-thymidine incorporation) when cells were added in the presence of chimeric anti-CD80 antibody and chimeric anti-CD86 antibody are shown. The vertical axis shows 3H-thymidine incorporation based on the case without antibody addition (Allo). 1 / 2, 1 / 4, 1 / 8, and 1 / 16 are the mixing ratios of cells obtained in the presence of chimeric anti-CD80 antibody and chimeric anti-CD86 antibody to naive responder cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] It should be understood that the terms used in this specification are used in the sense that they are commonly used in the field unless otherwise specified.Therefore, unless otherwise defined, all technical terms and scientific and technical terms used in this specification have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs.In case of conflict, this specification (including definitions) shall prevail.
[0015] (Definition of terms) As used herein, "about" means ±10% of the numerical value that follows.
[0016] As used herein, "immune tolerance" refers to a state in which a specific immune response to a specific antigen is not shown or the specific immune response is suppressed. Immune tolerance may refer to both or either of a state in which immune cells (especially T cells) do not show a specific immune response to a specific antigen or the specific immune response is suppressed, and a state in which a human does not show a specific immune response to a specific antigen or the specific immune response is suppressed. Immune tolerance has been attracting attention because it enables treatment of immune rejection reactions and treatment of allergies. As used herein, "anergy" refers to a state in which no costimulation is input when an antigen is presented from an antigen-presenting cell, and therefore the cell is unable to respond even if stimulated under costimulatory conditions the next time. As used herein, "PBMCs (or T cells) in which immune tolerance has been induced" and "anergy PBMCs (or T cells)" have the same meaning.
[0017] As used herein, a "subject" includes domestic animals (e.g., cows, sheep, cats, dogs, horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the subject is a human.
[0018] As used herein, "immunoactivation" refers to stimulation of cells of the immune system (e.g., macrophages, neutrophils, natural killer (NK) cells, T cells, B cells, etc.) and proliferation of cells of the immune system. Activation of cells of the immune system induces production of cytokines (e.g., INF) and cytotoxic activity.
[0019] As used herein, "does not substantially induce cytokine production due to immune activation" means resulting in cytokine production that is about 20% or less of the amount of cytokine produced by cells derived from a subject (e.g., macrophages, neutrophils, natural killer (NK) cells, T cells, B cells, etc.) in the presence of an antigen and in the absence of an antibody of the present disclosure.
[0020] In the present specification, the term "antibody" in the broad sense refers to a molecule or a group thereof that can specifically bind to a specific epitope on an antigen. In the present specification, the term "antibody" in the broad sense may be a full-length antibody (i.e., an antibody having an Fc portion) or an antibody lacking an Fc portion. An antibody lacking an Fc portion may be capable of binding to an antigen of interest, and examples of such an antibody include, but are not limited to, a Fab antibody, an F(ab')2 antibody, an Fab' antibody, an Fv antibody, and an scFv antibody. The antibody may be modified or unmodified. The modified antibody may be bound to various molecules such as polyethylene glycol. The modified antibody may be obtained by chemically modifying the antibody using a known method.
[0021] In the present specification, the term "antibody" in the narrow sense refers to an immunoglobulin or a group thereof that can specifically bind to a specific epitope on an antigen, and a variant thereof is referred to as a "variant of an antibody". In the present specification, the term "antibody" in the narrow sense may be a full-length antibody (i.e., an antibody having an Fc portion), and in the present specification, the term "variant of an antibody" may be a variant lacking the Fc portion of the antibody. Thus, in the present specification, an antibody in the narrow sense may be referred to as a full-length antibody, and a variant of an antibody may be referred to as a variant of a full-length antibody. A variant lacking an Fc portion may be capable of binding to an antigen of interest, and examples of such variants include, but are not limited to, Fab antibodies, F(ab')2 antibodies, Fab' antibodies, Fv antibodies, and scFv antibodies. In addition, the variant of an antibody includes modified or unmodified antibodies. The modified antibody may be bound to an antibody with various molecules such as polyethylene glycol. The modified antibody can be obtained by chemically modifying an antibody using a known method.
[0022] In one embodiment of the present disclosure, the "polyclonal antibody" can be produced, for example, by administering an immunogen containing an antigen of interest to a mammal (e.g., rat, mouse, rabbit, cow, monkey, etc.), bird, etc., to induce the production of a polyclonal antibody specific to the antigen. The administration of the immunogen may include the injection of one or more immunizing agents and, if desired, an adjuvant. Adjuvants may be used to increase the immune response and may include Freund's adjuvant (complete or incomplete), mineral gel (e.g., aluminum hydroxide), or surfactants (e.g., lysolecithin), etc. Immunization protocols are known in the art and may be performed by any method that induces an immune response in accordance with the host organism of choice (Protein Experiment Handbook, Yodosha (2003): 86-91.).
[0023] In one embodiment of the present disclosure, the term "monoclonal antibody" includes cases where the individual antibodies constituting the population are substantially identical to a single epitope, except for antibodies with a small amount of naturally occurring mutations. Alternatively, the individual antibodies constituting the population may be substantially identical to a single epitope, except for antibodies with a small amount of naturally occurring mutations. Monoclonal antibodies are highly specific and differ from conventional polyclonal antibodies, which typically contain different antibodies that correspond to different epitopes and / or different antibodies that correspond to the same epitope. In addition to their specificity, monoclonal antibodies are useful in that they can be synthesized from hybridoma cultures that are not contaminated by other immunoglobulins. The term "monoclonal" may indicate the characteristic of being obtained from a substantially homogeneous antibody population, but does not imply that the antibody must be produced by any particular method. For example, monoclonal antibodies may be produced by methods similar to the hybridoma method described in "Kohler G, Milstein C., Nature. 1975 Aug 7;256(5517):495-497." Alternatively, the monoclonal antibodies may be produced by recombinant methods similar to those described in U.S. Pat. No. 4,816,567. Alternatively, the monoclonal antibodies may be isolated from phage antibody libraries using techniques similar to those described in "Clackson et al., Nature. 1991 Aug 15;352(6336):624-628," or "Marks et al., J Mol Biol. 1991 Dec 5;222(3):581-597." Alternatively, the monoclonal antibodies may be produced by the methods described in "Protein Experiment Handbook, Yodosha (2003):92-96."
[0024] In one embodiment of the present disclosure, the "chimeric antibody" is, for example, a combination of an antibody variable region and an antibody constant region between different organisms, and can be constructed by genetic recombination techniques. A mouse-human chimeric antibody can be produced, for example, by the method described in "Roguska et al., Proc Natl Acad Sci US A. 1994Feb 1;91(3):969-973." The basic method for producing a mouse-human chimeric antibody is, for example, to link a mouse leader sequence and a variable region sequence present in a cloned cDNA to a sequence encoding a human antibody constant region already present in an expression vector for mammalian cells. Alternatively, the mouse leader sequence and the variable region sequence present in a cloned cDNA may be linked to a sequence encoding a human antibody constant region, and then linked to a mammalian cell expression vector. The fragment of the human antibody constant region can be any of the H chain constant region and the L chain constant region of a human antibody, and examples of the fragment include Cγ1, Cγ2, Cγ3, or Cγ4 for the human H chain, and Cλ or Cκ for the L chain.
[0025] In one embodiment of the present disclosure, a "humanized antibody" is an antibody that has, for example, one or more CDRs from a non-human species, a framework region (FR) from a human immunoglobulin, and a constant region from a human immunoglobulin, and binds to a desired antigen. Antibody humanization can be performed using various techniques known in the art (Almagro et al., Front Biosci. 2008 Jan 1;13:1619-1633.). For example, CDR grafting (Ozaki et al., Blood. 1999 Jun 1; 93(11): 3922-3930.), Re-surfacing (Roguska et al., Proc Natl Acad Sci US A. 1994 Feb 1; 91(3): 969-973.), or FR shuffling (Damschroder et al., Mol Immunol. 2007 Apr; 44(11): 3049-3060. Epub 2007 Jan 22.) can be used. To alter (preferably improve) antigen binding, amino acid residues in the human FR region may be replaced with corresponding residues from the CDR donor antibody. This FR replacement can be performed by methods well known in the art (Riechmann et al., Nature. 1988 Mar 24; 332(6162): 323-327.). For example, FR residues important for antigen binding may be identified by modeling the interactions of CDR and FR residues, or unusual FR residues at particular positions may be identified by sequence comparison.
[0026] In one embodiment of the present disclosure, the "human antibody" is, for example, an antibody whose heavy chain variable and constant regions and light chain variable and constant regions are derived from a gene encoding human immunoglobulin. Major production methods include the transgenic mouse method for producing human antibodies and the phage display method. In the transgenic mouse method for producing human antibodies, if a functional human Ig gene is introduced into a mouse in which endogenous Ig has been knocked out, human antibodies with diverse antigen-binding abilities are produced instead of mouse antibodies. Furthermore, if this mouse is immunized, human monoclonal antibodies can be obtained by the conventional hybridoma method. For example, they can be produced by the method described in "Lonberg et al., Int Rev Immunol.1995;13(1):65-93." The phage display method is a system in which a foreign gene is expressed as a fusion protein on the N-terminus of a coat protein (g3p, g10p, etc.) of a filamentous phage, such as M13 or T7, which is typically an Escherichia coli virus, so as not to lose the infectivity of the phage. For example, it can be prepared by the method described in "Vaughan et al., Nat Biotechnol. 1996 March;14(3):309-314."
[0027] As used herein, the term "modified sequence" refers to a sequence having at least one amino acid residue modification (substitution, addition or deletion) in the case of an amino acid sequence, and at least one base modification (substitution, addition or deletion) in the case of a nucleic acid sequence, which does not cause a frameshift. The modified sequence has a function similar to that of the original sequence, and is, for example, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the original sequence. When the original sequence is an antibody, the modified sequence preferably has no modification in the CDR, but may have one or more modifications as long as it maintains the binding ability or function of the original antibody, and preferably has three or less modifications, more preferably two or less modifications, and most preferably one modification. When introducing a modification into the CDR, a person skilled in the art can select an appropriate modification so as to maintain the binding ability or function of the original antibody.
[0028] As used herein, "cells derived from a subject" refers to cells obtained from a subject to which the composition of the present disclosure is administered, or cells derived from cells obtained from the subject. As used herein, "antigen derived from a subject" refers to an antigen produced by the subject itself that causes an immune response, for example, an antigen produced by the subject itself that causes an autoimmune disease in a subject with an autoimmune disease. As used herein, "antigen not derived from a subject" refers to a foreign antigen that can cause an immune response. As used herein, "antigen-containing material not derived from a subject" refers to any substance or collection of substances that contains an antigen not derived from a subject, such as a cell, cell population, tissue, etc. that expresses an antigen not derived from a subject.
[0029] As used herein, the term "transplant immune rejection" refers to a situation in which the immune system of a subject who has received an organ, tissue or cell transplant attacks and damages or destroys the transplanted organ, tissue or cell.
[0030] In this specification, "allergy" refers to the state that immune response occurs excessively against antigens that are not derived from the subject.The antigens that are not derived from the subject that cause allergy are also called allergens, and include, but are not limited to, mite antigens, egg white antigens, milk antigens, wheat antigens, peanut antigens, soybean antigens, buckwheat antigens, sesame antigens, rice antigens, crustacean antigens, kiwi antigens, apple antigens, banana antigens, peach antigens, tomato antigens, tuna antigens, salmon antigens, mackerel antigens, beef antigens, chicken antigens, pork antigens, cat dander antigens, insect antigens, pollen antigens, dog dander antigens, fungal antigens, bacterial antigens, latex, haptens and metals.
[0031] As used herein, the term "autoimmune disease" refers to any disease in which the immune system mounts an unwanted immune response against one's own cells, tissues, or organs. Examples of autoimmune diseases include, but are not limited to, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), systemic lupus erythematosus, psoriasis, scleroderma, autoimmune thyroid disease, alopecia areata, Graves' disease, Guillain-Barré syndrome, celiac disease, Sjogren's syndrome, rheumatic fever, gastritis, autoimmune atrophic gastritis, autoimmune hepatitis, insulitis, oophoritis, orchitis, uveitis, phacogenic uveitis, myasthenia gravis, primary myxedema, pernicious anemia, autoimmune hemolytic anemia, Addison's disease, Goodpasture's syndrome, nephritis (e.g., glomerulonephritis), pemphigus vulgaris, pemphigoid, sympathetic ophthalmia, idiopathic thrombocytopenic purpura, idiopathic leukopenia, Wegener's granulomatosis, and polymyositis / dermatomyositis.
[0032] As used herein, the term "graft-versus-host disease" refers to an immune response in which a transplanted organ, tissue or cell attacks, damages or destroys the cells, tissue or organ of the recipient subject.
[0033] As used herein, the term "immune rejection caused by transplantation of iPS cells or ES cells, or cells, tissues, or organs derived from these cells" refers to an immune rejection caused by an antigen carried by iPS cells or ES cells, or an antigen carried by cells, tissues, or organs derived from iPS cells or ES cells.
[0034] (Preferred embodiment) A description of a preferred embodiment will be given below, but it should be understood that this embodiment is an example of the present disclosure, and the scope of the present disclosure is not limited to such a preferred embodiment. It should also be understood that those skilled in the art can easily make modifications, changes, etc. within the scope of the present disclosure by referring to the following preferred examples. Regarding these embodiments, those skilled in the art can combine any embodiments as appropriate.
[0035] The present inventors attempted to induce an immune response (anergy) using an antibody having a human Fc region that inhibits the interaction between CD80 and / or CD86 and CD28, and found that it activates cells involved in the immune system, such as macrophages, neutrophils, and natural killer (NK) cells, and induces the release of humoral factors such as interleukins and interferons (IFNs) that control immune responses. Since the release of these humoral factors induces undesirable activation of the immune system, which is the opposite of immune tolerance, the inventors newly discovered that induction of an immune response (anergy) using an antibody having a human Fc region has the problem of weakening the effect of immune tolerance, and found that the effect of immune tolerance can be improved by adjusting this human Fc region.
[0036] Specifically, chimeric antibodies that inhibit the interaction between CD80 and / or CD86 and CD28 and induce immune tolerance were developed by immunizing Balb / c mice with recombinant human CD80 / CD86-Fc fusion protein, extracting mRNA from the spleen of the mice, synthesizing cDNA, and constructing a phage display library using the amplified genes by RT-PCR. The libraries were then used to select Fab antibodies with high affinity to CD80 / CD86, and the human Fc region was then added to the phage display library. minutes was produced by genetic engineering.
[0037] In order to minimize the rejection reaction against the antibody used for immune tolerance induction, the inventors humanized the chimeric antibody by the CDR grafting method developed by Xoma, Inc., and produced a humanized antibody (subclass: IgG1). The obtained humanized anti-CD80 antibody and anti-CD86 antibody (subclass: IgG1) were added to a mixed lymphocyte reaction using PBMCs (peripheral blood mononuclear cells) collected from two volunteers assumed to be donors and recipients, and the inhibitory function of the induced cells upon the same antigen stimulation was evaluated. Specifically, PBMCs were collected from one volunteer and irradiated with 30 Gy radiation, and co-cultured with PBMCs collected from another volunteer in the presence of humanized anti-CD80 / CD86 antibodies for 7 days to induce donor antigen-specific anergy cells. The induced cells were added at a certain ratio to mixed lymphocytes of the same recipient and donor, and the inhibitory ability of cell division and proliferation upon antigen stimulation was measured as the amount of tritium-labeled thymidine incorporation. As a result, it was confirmed that humanized anti-CD80 and anti-CD86 antibodies significantly suppressed the amount of thymidine uptake, and that the cells induced using these antibodies newly acquired suppressive function.
[0038] However, when the amount of IFNγ in the supernatant after 7 days of culture was measured, it was found that IFNγ was produced when antibodies were added even without antigen stimulation.In addition, it was revealed that the amount of IFNγ normally produced upon alloantigen stimulation with irradiated PBMCs was present in the supernatant in almost the same amount even when antibodies were added.
[0039] Therefore, the present inventors conducted extensive research to obtain an antibody that does not induce IFN-γ production while maintaining the ability to induce immune tolerance. As a result, they found that by using a humanized anti-CD80 / CD86 antibody with a subclass of IgG2 or IgG4, cells that induce immune tolerance without producing IFN-γ can be obtained.
[0040] (antibody) In one aspect of the present disclosure, the present disclosure provides an antibody that inhibits the interaction between CD80 and / or CD86 expressed on the cell surface of a cell and CD28 expressed on the cell surface of another cell, and does not substantially induce cytokine production by immune activation. The antibody of the present disclosure may be an anti-CD80 antibody and / or an anti-CD86 antibody, a bispecific antibody against CD80 and CD86, an anti-CD28 antibody, or a mixture thereof. In some embodiments, the Fc portion of the antibody of the present disclosure may be a portion that does not substantially induce cytokine production by immune activation. In certain embodiments, the subclass of the antibody of the present disclosure is IgG2 or IgG4. The antibody of the present disclosure having the subclass IgG2 or IgG4 surprisingly did not induce any cytokine production by cells of the immune system. The antibody used in the present disclosure is preferably an antagonistic antibody, since agonizing the receptor may cause undesirable effects.
[0041] In some embodiments, an antibody that does not substantially induce cytokine production due to immune activation may result in cytokine production that is about 20% or less, preferably about 10% or less, more preferably about 5% or less, and most preferably about 0%, of the amount of cytokine produced by cells derived from a subject (e.g., macrophages, neutrophils, natural killer (NK) cells, T cells, B cells, etc.) in the absence of an antibody of the present disclosure.
[0042] As used herein, the term "antagonistic (antibody)" is synonymous with antagonist (antibody), inhibiting (antibody), or blocking (antibody), and refers to a substance (in the case of antibodies, an antibody) that has the function of inhibiting a target function or signal and weakening or inactivating the action of the living body.
[0043] As described above, by changing the antibody subclass from IgG1 to IgG2 or IgG4, the induction of cytokine production was unexpectedly suppressed. Without wishing to be bound by theory, it is believed that the induction of cytokine production is due to the Fc portion of the IgG1 antibody, since the functions mediated by the Fc portion differ between IgG subclasses. Thus, in another embodiment, the antibody of the present disclosure may be an antibody lacking an Fc portion. Examples of such antibodies include, but are not limited to, Fab antibodies, F(ab')2 antibodies, Fab' antibodies, Fv antibodies, and scFv antibodies.
[0044] In some embodiments, the cells expressing CD80 and / or CD86 may be antigen presenting cells and the other cells expressing CD28 may be T cells.
[0045] In another aspect of the present disclosure, the antibody of the present disclosure is characterized in that it can inhibit the interaction between CD80 and / or CD86 expressed on the cell surface and CD28 expressed on the surface of another cell. Whether or not a candidate antibody can inhibit the interaction between CD80 and / or CD86 expressed on the cell surface and CD28 expressed on the surface of another cell can be determined, for example, by co-immunoprecipitation. Specifically, after binding these proteins, immunoprecipitation is performed using an antibody that binds to one of the proteins (bait), and the other immunoprecipitated protein (prey) is measured. If the amount of prey contained in the immunoprecipitate decreases when the candidate antibody is added compared to a control that does not contain the candidate antibody, the candidate antibody is determined to inhibit the binding between proteins. The prey contained in the immunoprecipitate can be measured by labeling the prey as necessary. In addition, a pull-down assay may be used to bind one of the proteins (bait) to a carrier, contact the other protein (prey) in the presence / absence of the candidate antibody, and compare the amount of prey bound to the carrier.
[0046] Preferably, the antibody of the present disclosure can inhibit the interaction between CD80 and / or CD86 expressed on the surface of an antigen-presenting cell and CD28 expressed on the surface of a T cell. Whether or not a candidate antibody inhibits the interaction between CD80 and / or CD86 expressed on the surface of an antigen-presenting cell and CD28 expressed on the surface of a T cell can be determined by contacting an antigen-presenting cell expressing CD80 and / or CD86 with a T cell expressing CD28 in the presence of the candidate antigen antibody, and determining whether the antibody inhibits the interaction between CD80 and / or CD86 expressed on the surface of an antigen-presenting cell and CD28 expressed on the surface of a T cell when the T cell is not activated.
[0047] The antibody of the present disclosure is also characterized in that it does not promote cytokine production by human PBMC. Whether or not a candidate antibody promotes cytokine production by human PBMC can be determined by contacting the candidate antibody with human PBMC in a medium and measuring the amount of cytokine released into the medium. A candidate antibody that releases less / more cytokine in the presence of the candidate antibody compared to the amount of cytokine released by human PBMC in the absence of the antibody is determined to not promote / promote cytokine production by human PBMC. Examples of cytokines include interleukins such as IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-9, IL-14, IL-15, IL-17, and IL-18; chemokines such as CC, CXC, CX3C, and C; interferons such as IFNα, IFNβ, and IFNγ; and cytotoxic factors such as TNFα. Preferably, it is an inflammatory cytokine, more preferably IFNγ. Cytokines can be measured using a commercially available kit. For example, IFNγ can be measured using Human IFNγ ELISA MAX™ Deluxe (Bioligands).
[0048] Preferably, the antibody of the present disclosure can induce immune tolerance to an antigen by contacting PBMCs together with the antigen or cells having the antigen on their surface. Whether or not a candidate antibody can induce immune tolerance to an antigen by contacting PBMCs together with the antigen or cells having the antigen on their surface can be determined by contacting the antigen or cells having the antigen on their surface with PBMCs in the presence of the candidate antibody for several to seven days, and then 3 H-thymidine was added 3 In the culture medium 16–20 h after addition of H-thymidine 3 After H-thymidine removal, PBMC 3 The amount of H-thymidine incorporation by PBMCs can be measured by measuring the amount of H-thymidine incorporation by PBMCs in the presence of the candidate antibody compared to the control in which the candidate antibody was not administered. 3If the amount of 3H-thymidine incorporation is low, it can be determined that the antibody is capable of inducing immune tolerance to the antigen by contacting PBMCs with the antigen or cells having the antigen on their surface.
[0049] As used herein, "immune tolerance" refers to a state in which a specific immune response to a specific antigen is not shown or the specific immune response is suppressed. Immune tolerance may refer to both or either a state in which immune cells (particularly T cells) do not show a specific immune response to a specific antigen or the specific immune response is suppressed, and a state in which a human does not show a specific immune response to a specific antigen or the specific immune response is suppressed. As used herein, "anergy" refers to T cells that are unable to respond even when stimulated under conditions with costimulation the next time because no costimulation is input when an antigen is presented by an antigen-presenting cell. As used herein, "PBMCs (or T cells) in which immune tolerance has been induced" and "anergy PBMCs (or T cells)" have the same meaning.
[0050] Preferably, the present disclosure relates to anti-CD80 and anti-CD86 antibodies. As used herein, anti-CD80 and anti-CD86 antibodies specifically bind to CD80 and CD86, respectively. As used herein, an antibody "specifically" binds means that the antibody binds to a protein of interest (CD80 or CD86) with substantially higher affinity than the antibody binds to other proteins or peptides. Here, "binding with substantially high affinity" means that the specific protein or peptide of interest can be detected by a desired measurement device or method in a manner that distinguishes it from other proteins or peptides. For example, substantially high affinity may mean that the intensity (e.g., fluorescence intensity) detected by ELISA or EIA is about 3 times or more, about 4 times or more, about 5 times or more, about 6 times or more, about 7 times or more, about 8 times or more, about 9 times or more, about 10 times or more, about 20 times or more, about 30 times or more, about 40 times or more, about 50 times or more, or about 100 times or more.
[0051] The binding rate constant (Ka1) of the antibody of the present disclosure to CD80, CD86, or CD28 is, for example, about 1 × 10 4 Ms -1 More than that, about 1×10 5 Ms -1 That's about 5 x 10 5 Ms -1 The dissociation rate constant (Kd1) of the antibody of the present disclosure binding to CD80, CD86, or CD28 is, for example, about 1 × 10 -3 Below, approximately 1×10 -4 The binding constant (KD) of the antibody of the present disclosure to CD80, CD86, or CD28 is, for example, about 1×10 -8 (M) or less, approximately 5 x 10 -8 (M) or less, approximately 1×10 -9 (M) or less, approximately 5 x 10 -9 The binding rate constant (Ka1), dissociation rate constant (Kd1), and binding constant (KD) of the antibody herein can be determined by using BIACORE (GE Healthcare Biosciences, BIACORE-X100) in accordance with the manufacturer's manual, immobilizing biotinylated CD80, CD86, or CD28 or cells expressing these on an SA chip, pouring in a test antibody, measuring the binding rate constant Ka1 and dissociation rate constant Kd1, and determining the binding constant KD value using bivalent fitting.
[0052] The antibody of the present disclosure may be a polyclonal antibody or a monoclonal antibody, but is preferably a monoclonal antibody. In the present disclosure, a "monoclonal antibody" is an antibody with a uniform structure that reacts with a single antigenic determinant. Furthermore, the antibody of the present disclosure includes an antibody having an amino acid sequence of a non-human animal antibody and an amino acid sequence of an antibody derived from a human, and a human antibody. Examples of the non-human animal antibody include antibodies of mice, rats, hamsters, guinea pigs, rabbits, dogs, monkeys, sheep, goats, camels, chickens, ducks, etc., and preferably antibodies of animals that can produce hybridomas, more preferably antibodies of mice, rats, or rabbits. Examples of the antibody having an amino acid sequence of a non-human animal antibody and an amino acid sequence of an antibody derived from a human include human chimeric antibodies and humanized antibodies. In the above, the term "chimeric antibody" refers to an antibody derived from a non-human animal, which specifically binds to a target antigen (CD80, CD86, or CD28) and has been genetically modified to have the same constant region as a human antibody, and is preferably a human-mouse chimeric antibody (see European Patent Publication EP0125023). The term "humanized antibody" refers to an antibody derived from a non-human animal, which specifically binds to CD80, CD86, or CD28, and has been genetically modified to have a primary structure other than the complementary recognition regions (CDRs) of the H and L chains of the antibody, which has been genetically modified to a primary structure corresponding to a human antibody. Here, the CDR may be as defined by Kabat et al. ("Sequences of Proteins of Immunological Interest", Kabat, E. et al., USDepartment of Health and Human Services, 1983) or Chothia et al. (Chothia & Lesk (1987) J. Mol. Biol., 196:901-917). The term "human antibody" refers to a human antibody that is an expression product of an antibody gene derived entirely from a human, and examples of such antibodies include monoclonal antibodies produced using transgenic animals into which genes involved in human antibody production have been introduced (see European Patent Publication EP0546073).For example, when the antibody of the present disclosure is used for treatment, prevention, or diagnosis by administering it to the body, the antibody of the present disclosure is preferably a human-non-human animal chimeric antibody, a humanized antibody, or a human antibody.
[0053] Preferably, the immunoglobulin class of the antibody of the present disclosure is IgG. Furthermore, the subclass of the antibody of the present disclosure is preferably IgG2 or IgG4. More preferably, the subclass of the antibody of the present disclosure is IgG4. Alternatively, preferably, the subclass of the antibody of the present disclosure is IgG2. Furthermore, the antibody of the present disclosure may be monospecific, bispecific (bispecific antibody), trispecific (trispecific antibody) (e.g., WO1991 / 003493), tetraspecific (tetraspecific antibody), or more multispecific (multiple antigen specificities).
[0054] In one embodiment, an antibody of the disclosure has a CDRH3 of the amino acid sequence set forth in SEQ ID NO: 27 or SEQ ID NO: 33. Preferably, an antibody of the disclosure has a CDRH1 of the amino acid sequence set forth in SEQ ID NO: 25, a CDRH2 of the amino acid sequence set forth in SEQ ID NO: 26, and a CDRH3 of the amino acid sequence set forth in SEQ ID NO: 27, or alternatively has a CDRH1 of the amino acid sequence set forth in SEQ ID NO: 31, a CDRH2 of the amino acid sequence set forth in SEQ ID NO: 32, and a CDRH3 of the amino acid sequence set forth in SEQ ID NO: 33. More preferably, the antibody of the present disclosure has a CDRH1 having the amino acid sequence set forth in SEQ ID NO:25, a CDRH2 having the amino acid sequence set forth in SEQ ID NO:26, and a CDRH3 having the amino acid sequence set forth in SEQ ID NO:27, and also has a CDRL1 having the amino acid sequence set forth in SEQ ID NO:28, a CDRL2 having the amino acid sequence set forth in SEQ ID NO:29, and a CDRL3 having the amino acid sequence set forth in SEQ ID NO:30, or has a CDRH1 having the amino acid sequence set forth in SEQ ID NO:31, a CDRH2 having the amino acid sequence set forth in SEQ ID NO:32, and a CDRH3 having the amino acid sequence set forth in SEQ ID NO:33, and also has a CDRL1 having the amino acid sequence set forth in SEQ ID NO:34, a CDRL2 having the amino acid sequence set forth in SEQ ID NO:35, and a CDRL3 having the amino acid sequence set forth in SEQ ID NO:36.
[0055] In one embodiment, the antibody of the present disclosure may be an antibody having a heavy chain having the amino acid sequence set forth in SEQ ID NO: 38 or 42, or a modified sequence thereof, and a light chain having the amino acid sequence set forth in SEQ ID NO: 40 or 44, or a modified sequence thereof, or a variant thereof. Preferably, the antibody of the present disclosure may be an antibody or a variant thereof comprising: (a) a VH comprising CDRH1 of the amino acid sequence set forth in SEQ ID NO: 53 or a modified sequence thereof, CDRH2 of the amino acid sequence set forth in SEQ ID NO: 54 or a modified sequence thereof, and CDRH3 of the amino acid sequence set forth in SEQ ID NO: 55 or a modified sequence thereof, and a VL comprising CDRL1 of the amino acid sequence set forth in SEQ ID NO: 56 or a modified sequence thereof, CDRL2 of the amino acid sequence set forth in SEQ ID NO: 57 or a modified sequence thereof, and CDRL3 of the amino acid sequence set forth in SEQ ID NO: 58 or a modified sequence thereof; or (b) a VH comprising CDRH1 of the amino acid sequence set forth in SEQ ID NO: 59 or a modified sequence thereof, CDRH2 of the amino acid sequence set forth in SEQ ID NO: 60 or a modified sequence thereof, and CDRH3 of the amino acid sequence set forth in SEQ ID NO: 61 or a modified sequence thereof, and a VL comprising CDRL1 of the amino acid sequence set forth in SEQ ID NO: 62 or a modified sequence thereof, CDRL2 of the amino acid sequence set forth in SEQ ID NO: 63 or a modified sequence thereof, and CDRL3 of the amino acid sequence set forth in SEQ ID NO: 64 or a modified sequence thereof. In a specific embodiment, the antibody or a variant thereof may comprise (a) a VH having the amino acid sequence set forth in SEQ ID NO: 46 or a modified sequence thereof and a VL having the amino acid sequence set forth in SEQ ID NO: 48 or a modified sequence thereof, or (b) a VH having the amino acid sequence set forth in SEQ ID NO: 50 or a modified sequence thereof and a VL having the amino acid sequence set forth in SEQ ID NO: 52 or a modified sequence thereof. The modified sequence preferably does not contain any modification (amino acid substitution, addition or deletion) in the CDR, but may contain several modifications (three or less, two or less, preferably one or less) in each CDR, so long as the binding ability and / or function of the antibody before modification is maintained. The modified sequence may preferably have at least 90% identity to the original sequence.
[0056] In another aspect, the antibody of the present disclosure relates to an antibody having a VH having the amino acid sequence set forth in SEQ ID NO: 18 or SEQ ID NO: 22. Preferably, the antibody of the present disclosure has a VH having the amino acid sequence set forth in SEQ ID NO: 18 and a VL having the amino acid sequence set forth in SEQ ID NO: 20, or has a VH having the amino acid sequence set forth in SEQ ID NO: 22 and a VL having the amino acid sequence set forth in SEQ ID NO: 24.
[0057] Furthermore, the present disclosure relates to an antibody in which the VH has an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions with a nucleic acid sequence encoding the amino acid sequence set forth in SEQ ID NO: 18 or SEQ ID NO: 22. Preferably, the present disclosure relates to an antibody in which the VH has an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions with a nucleic acid sequence encoding the amino acid sequence set forth in SEQ ID NO: 18, and the VL has an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions with a nucleic acid sequence encoding the amino acid sequence set forth in SEQ ID NO: 20, or an antibody in which the VH has an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions with a nucleic acid sequence encoding the amino acid sequence set forth in SEQ ID NO: 22, and the VL has an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions with a nucleic acid sequence encoding the amino acid sequence set forth in SEQ ID NO: 24. In the present specification, hybridizing under stringent conditions means hybridizing under hybridization conditions commonly used by those skilled in the art. For example, whether or not hybridization occurs can be determined by the method described in Molecular Cloning, a Laboratory Manual, Fourth Edition, Cold Spring Harbor Laboratory Press (2012) or Current Protocols in Molecular Biology, Wiley Online Library, etc. For example, the hybridization conditions may be hybridization in 6×SSC (0.9 M NaCl, 0.09 M trisodium citrate) or 6×SSPE (3 M NaCl, 0.2 M NaH2PO4, 20 mM EDTA 2Na, pH 7.4) at 42° C., followed by washing with 0.5×SSC at 42° C.
[0058] The present disclosure also includes an antibody in which the VH has an amino acid sequence having 80% or more identity with the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 22. Preferably, the antibody of the present disclosure has an amino acid sequence in which the VH has 80% or more identity with the amino acid sequence of SEQ ID NO: 18, and the VL has 80% or more identity with the amino acid sequence of SEQ ID NO: 20, or the VH has 80% or more identity with the amino acid sequence of SEQ ID NO: 22, and the VL has 80% or more identity with the amino acid sequence of SEQ ID NO: 24. The identity of the amino acid sequence means the percentage (%) of the number of amino acids whose types are the same in the range of the amino acid sequences to be compared between two types of proteins, and can be determined using known programs such as BLAST and FASTA. The identity may be higher than 80% and may be, for example, 85% or more, 90% or more, 95% or more, 98% or more, or 99% or more.
[0059] An antibody having an amino acid sequence encoded by a nucleic acid sequence that hybridizes to the above-mentioned VH under stringent conditions, and an antibody having an amino acid sequence with 80% or more identity thereto, preferably has the above-mentioned CDR sequence.
[0060] As a more specific example, the present disclosure includes an antibody having a heavy chain having an amino acid sequence set forth in one of SEQ ID NOs: 2, 6, 10, and 14. Preferably, the antibody of the present disclosure has a heavy chain having an amino acid sequence set forth in SEQ ID NO: 2 and a light chain having an amino acid sequence set forth in SEQ ID NO: 4, or has a heavy chain having an amino acid sequence set forth in SEQ ID NO: 6 and a light chain having an amino acid sequence set forth in SEQ ID NO: 8, or has a heavy chain having an amino acid sequence set forth in SEQ ID NO: 10 and a light chain having an amino acid sequence set forth in SEQ ID NO: 12, or has a heavy chain having an amino acid sequence set forth in SEQ ID NO: 14 and a light chain having an amino acid sequence set forth in SEQ ID NO: 16.
[0061] In a preferred embodiment, the antibody may comprise (a) a VH comprising a CDRH1 of the amino acid sequence set forth in SEQ ID NO: 25, a CDRH2 of the amino acid sequence set forth in SEQ ID NO: 26, and a CDRH3 of the amino acid sequence set forth in SEQ ID NO: 27, and a VL comprising a CDRL1 of the amino acid sequence set forth in SEQ ID NO: 28, a CDRL2 of the amino acid sequence set forth in SEQ ID NO: 29, and a CDRL3 of the amino acid sequence set forth in SEQ ID NO: 30, or (b) a VH comprising a CDRH1 of the amino acid sequence set forth in SEQ ID NO: 31, a CDRH2 of the amino acid sequence set forth in SEQ ID NO: 32, and a CDRH3 of the amino acid sequence set forth in SEQ ID NO: 33, and a VL comprising a CDRL1 of the amino acid sequence set forth in SEQ ID NO: 34, a CDRL2 of the amino acid sequence set forth in SEQ ID NO: 35, and a CDRL3 of the amino acid sequence set forth in SEQ ID NO: 36. In another preferred embodiment, the antibody may comprise (a) a VH having the amino acid sequence set forth in SEQ ID NO: 18 or a modified sequence thereof and a VL having the amino acid sequence set forth in SEQ ID NO: 20 or a modified sequence thereof (b) a VH having the amino acid sequence set forth in SEQ ID NO: 22 or a modified sequence thereof and a VL having the amino acid sequence set forth in SEQ ID NO: 24 or a modified sequence thereof. The modified sequence preferably does not contain any modifications (amino acid substitution, addition, or deletion) in the CDRs, but may contain several modifications (three or less, two or less, preferably one or less) in each CDR, so long as the binding ability and / or function of the antibody before modification is maintained. The modified sequence may preferably have at least 90% identity to the original sequence.
[0062] The antibody of the present disclosure can be produced by immunizing a non-human animal that generates an immune response, preferably a non-human animal that generates an immune response against itself (autoantibody) by hyperimmunization (e.g., MRL / lpr mouse), with CD80, CD86, or CD28 protein or its extracellular domain, or a cell expressing CD80, CD86, or CD28 as an immunogen, together with an immunostimulant as necessary (e.g., mineral oil or aluminum precipitate and heat-killed bacteria or lipopolysaccharide, Freund's complete adjuvant, Freund's incomplete adjuvant, etc.). The immunized animal is not particularly limited as long as it is an animal capable of producing hybridomas, such as mouse, rat, hamster, guinea pig, rabbit, dog, monkey, sheep, goat, chicken, duck, etc., but is preferably a mouse or rat, more preferably a mouse, and most preferably an MRL / lpr mouse. The immunogen is administered to the animal at a concentration of, for example, 1×10 6 The cells can be injected once or several times at appropriate intervals (usually once every 1-6 weeks, for a total of about 2-10 times) by subcutaneous, intraperitoneal, intravenous, intradermal, intramuscular or footpad injection. One to two weeks after the final immunization, blood is collected from the orbit or tail vein of the immunized animal, and the serum is used to measure the antibody titer. The antibody of the present disclosure can be obtained by purification from the serum of an animal that exhibits a sufficient antibody titer.
[0063] Monoclonal antibodies can be obtained by culturing hybridomas obtained by fusing antibody-producing cells obtained from immunized animals immunized by the above method with myeloma cells. Examples of the fusion method include the method of Milstein et al. (Galfre, G. & Milstein, C. (1981) Methods Enzymol., 73:3-46). The antibody-producing cells used can be collected from the spleen, pancreas, lymph nodes, or peripheral blood of mice or rats immunized by the above method and whose serum shows sufficient antibody titers. The myeloma cells used are not particularly limited as long as they are derived from mammals such as mice, rats, guinea pigs, hamsters, rabbits, or humans and can grow in vitro. Examples of such cells include P3-X63Ag8(X63) (Nature, 256, 495, 1975), P3 / NS1 / 1-Ag4-1(NS1) (Eur. J. Immunol., 6, 292, 1976), P3X63Ag8U1(P3U1) (Curr. Top. Microbiol. Immunol., 81, 1, 1978), and P3X63Ag8.653(653) (J. Immunol., 2003, 14, 1978). Examples of such cells include Sp2 / 0-Ag14 (Sp2 / O) (Nature, 276, 269, 1978), Sp2 / O / FO-2 (FO-2) (J. Immunol. Methods, 35, 1, 1980), and SP2ab. Preferably, the cells are derived from the same animal species as the antibody-producing cells, and more preferably, the cells are derived from an animal of the same lineage as the antibody-producing cells.
[0064] After culturing, the culture supernatant is collected, and clones that bind to CD80, CD86, or CD28 are selected by ELISA using CD80, CD86, or CD28 proteins or their extracellular domains, or cells expressing CD80, CD86, or CD28. The selected clones are subjected to limiting dilution 1 to 5 times to separate them into single cells, thereby obtaining cells that produce monoclonal antibodies.
[0065] Alternatively, for example, an antibody that binds to CD80, CD86, or CD28 can be obtained by using an antibody phage library (Tomizuka et al., Nature Genet., 15, 146-156 (1997)). When an antibody phage library is used, for example, CD80, CD86, or CD28 protein or its extracellular domain, or cells expressing CD80, CD86, or CD28 are immobilized on a solid phase, reacted with a phage antibody library, and unbound phages are washed away, and then bound phages are recovered to obtain a desired clone (panning).
[0066] Alternatively, the amino acid sequence of the antibody of interest or its immunoreactive fragment can be designed with reference to the amino acid sequences described herein, DNA encoding the designed amino acid sequence can be prepared, incorporated into an expression vector, and the vector can be introduced into an appropriate host cell to express the antibody obtained. From the obtained antibodies, antibodies having high specificity to CD80, CD86, or CD28 can be screened according to the above-mentioned method.
[0067] When the antibody of the present disclosure is a human chimeric antibody, it can be obtained by preparing DNA encoding the VHVL of a non-human animal monoclonal antibody, combining it with cDNA for the constant region of human immunoglobulin, incorporating it into an expression vector, and introducing the vector into a suitable host cell for expression (Morrison, SL et al., Proc. Natl. Acad. Sci. USA, 81, 6851-6855, 1984).
[0068] When the antibody of the present disclosure is a humanized antibody, it can be obtained by constructing a DNA encoding a V region in which an amino acid sequence encoding the CDR of the VHVL of a non-human animal monoclonal antibody is grafted to the Framework Region (FR) of the VHVL of a human antibody, combining the constructed DNA with a constant region cDNA of a human-derived immunoglobulin, incorporating the DNA into an expression vector, and expressing the vector by introducing it into an appropriate host cell (see L. Rieohmann et al., Nature, 332, 323, 1988; Kettleborough, CA et al., Protein Eng., 4, 773-783, 1991; Clark M., Immunol.Today., 21, 397-402, 2000). The CDR of a non-human animal monoclonal antibody can be obtained by comparing the amino acid sequence predicted from the DNA sequence encoding the VHVL of the non-human animal monoclonal antibody obtained by the above-mentioned method with the entire amino acid sequence of the VHVL of a known antibody. The amino acid sequence of a known antibody can be obtained, for example, from the amino acid sequence of an antibody registered in a database such as the Protein Data Bank. The FR of the humanized antibody is not particularly limited as long as the grafted antibody exhibits the effects of the present disclosure, but is preferably a human antibody FR whose variable region (hereinafter referred to as "V region") has a three-dimensional structure similar to that of the V region of the non-human animal monoclonal antibody from which the CDR is derived, or a human antibody FR that is highly homologous to the amino acid sequence of the FR of the non-human animal monoclonal antibody used. In a humanized antibody, a part of the amino acids constituting the FR derived from a human antibody (particularly, amino acids present at a position three-dimensionally close to the CDR) may be replaced with the FR sequence of the non-human animal monoclonal antibody from which the CDR is derived, as necessary (see Queen et al., U.S. Patent No. 5,585,089). The DNA sequence encoding the V region of the humanized antibody used is designed as a DNA sequence corresponding to the amino acid sequence obtained by combining the amino acid sequence of the CDR of the non-human animal monoclonal antibody and the amino acid sequence of the FR of the human antibody. DNA encoding the V region of a humanized antibody can be prepared based on the designed DNA sequence by methods well known to those skilled in the art.
[0069] Human antibodies can be obtained, for example, by using a human antibody phage library or a human antibody-producing transgenic mouse (Tomizuka et al., Nature Genet., 15, 146-156 (1997)). When a human antibody phage library is used, for example, CD80, CD86 or CD28 protein or its extracellular domain, or cells expressing CD80, CD86 or CD28 are bound to a solid phase, reacted with a phage antibody library, and unbound phages are washed away, and then bound phages are collected to obtain a desired clone (panning). A human antibody-producing transgenic mouse is a mouse in which an Ig gene of a human antibody is introduced into a mouse in which an endogenous immunoglobulin (Ig) gene has been knocked out. A human antibody that specifically recognizes CD80, CD86 or CD28 can be obtained by immunizing a human antibody-producing transgenic mouse with an antigen protein according to the antibody production method of the present disclosure described above.
[0070] (Nucleic acid molecules, vectors, host cells) In another aspect, the present disclosure relates to a nucleic acid molecule having a polynucleotide encoding the antibody of the present disclosure. For example, the nucleic acid molecule of the present disclosure comprises a nucleotide sequence as SEQ ID NO: 17 or SEQ ID NO: 21 as VH. In another aspect, the nucleic acid molecule of the present disclosure comprises a nucleotide sequence as SEQ ID NO: 19 or SEQ ID NO: 23 as VL. As a more specific example, the nucleic acid molecule of the present disclosure contains a polynucleotide encoding a VH having a nucleotide sequence as selected from SEQ ID NO: 1, 5, 9, and 13, and a polynucleotide encoding a VL having a nucleotide sequence as selected from SEQ ID NO: 3, 7, 11, and 15. The nucleic acid molecule of the present disclosure may have a nucleic acid sequence that hybridizes with the above-mentioned SEQ ID NO under stringent conditions. Furthermore, the present disclosure encompasses a vector having the nucleic acid molecule. Such a vector is not particularly limited as long as it is a vector that can be used for expressing an antibody, and can be selected according to the host to be used, such as an appropriate viral vector or plasmid vector. In another aspect, the present disclosure relates to a host cell containing the vector. The host cell is not particularly limited as long as it is a host cell that can be used to express an antibody, and examples thereof include mammalian cells (mouse cells, rat cells, rabbit cells, human cells, etc.), yeast, and microorganisms (Escherichia coli, etc.). The present disclosure includes a method for producing the antibody of the present disclosure, which includes culturing the host cell described above. The medium culture method can be appropriately determined by means well known to those skilled in the art depending on the host cell used.
[0071] The nucleic acid of the present disclosure can be obtained by cloning from a hybridoma producing the antibody obtained above, or by appropriately designing a nucleic acid sequence based on the amino acid sequence of the antibody or its immunoreactive fragment obtained above. The vector of the present disclosure can be obtained by appropriately incorporating the obtained nucleic acid into a vector suitable for expression. In addition to the nucleic acid of the present disclosure, the vector of the present disclosure may contain a region required for expression (promoter, enhancer, terminator, etc.). In addition, the host cell of the present disclosure can be obtained by introducing the vector of the present disclosure into an appropriate cell line (for example, animal cells, insect cells, plant cells, yeast, microorganisms such as E. coli).
[0072] (composition) In one aspect of the disclosure, the disclosure provides a composition for making immune tolerance-induced cells, comprising at least one of the antibodies described herein. In one embodiment of the disclosure, the composition may comprise an anti-CD80 antibody, an anti-CD86 antibody, an anti-CD28 antibody, or a bispecific antibody against CD80 and CD86, or any combination thereof. The immune tolerance-induced cells may be administered to a subject who has received an organ transplant, for example, to reduce rejection of the organ transplant. The immune tolerance-induced cells may be cells derived from the subject (recipient) or a donor, or a mixture of these. The composition of the disclosure surprisingly does not substantially induce the release of cytokines by cytokine-producing cells (e.g., macrophages, neutrophils, natural killer (NK) cells). Not inducing the release of cytokines is advantageous, since cytokines attenuate immune tolerance.
[0073] In another aspect, the present disclosure relates to a medical composition containing the antibody described herein. In one example, the medical composition of the present disclosure includes an anti-CD80 antibody, an anti-CD86 antibody, an anti-CD28 antibody, or a bispecific antibody against CD80 and CD86. The medical composition of the present disclosure can be used to induce immune tolerance. Throughout the present specification, "to induce immune tolerance" includes, for example, to induce immune tolerance to a transplanted organ, i.e., to suppress rejection in organ transplantation, and to suppress excessive immune responses to causative substances that act as immunogens in patients with autoimmune or allergic diseases, thereby alleviating symptoms or treating these diseases. In another embodiment, the pharmaceutical composition of the present disclosure is used to generate cells in which immune tolerance has been induced.
[0074] In the "organ transplantation" in this specification, examples of the "organ" to be transplanted include, but are not limited to, the heart, kidney, lung, pancreas, esophagus, stomach, small intestine, large intestine, skin, nerve, blood, blood cells including immune system cells, bone, cartilage, blood vessel, cornea, eyeball, bone marrow, or liver. In addition, in this specification, "organ" includes not only the whole organ or organ mass, but also parts of organs or cells that constitute organs. For example, cardiac muscle cells and corneal cells are also included in transplanted organs. In addition, organ transplantation includes not only the transplantation of another person's organ into a patient, but also the transplantation of an organ produced using allogeneic stem cells in regenerative medicine, etc. into a patient.
[0075] The antibody of the present disclosure can be used as a medical composition by purifying it as necessary and then formulating it according to a conventional method. The present disclosure also includes the use of the antibody of the present disclosure for producing a medical composition for inducing immune tolerance. Alternatively, the present disclosure includes the use of the antibody of the present disclosure for inducing immune tolerance. Furthermore, the present disclosure relates to a method for inducing immune tolerance, which includes adding or administering the antibody of the present disclosure. For example, the present disclosure includes a method for suppressing rejection in organ transplantation, which includes administering the antibody of the present disclosure to a patient receiving an organ transplantation, a method for treating an autoimmune disease or an allergic disease, which includes administering the antibody of the present disclosure to a patient suffering from an autoimmune disease or an allergic disease, and a method for suppressing rejection in transplantation of iPS cells or ES cells, or cells, tissues, or organs derived from (differentiated from) these cells, which includes administering the antibody of the present disclosure to a patient receiving an iPS cell or ES cell, or cells, tissues, or organs derived from these cells.
[0076] Examples of cells, tissues, or organs derived from (differentiated from) iPS cells or ES cells include, but are not limited to, nerve cells or tissue, corneal cells or tissue, cardiac muscle cells or tissue, liver or tissue, cartilage cells or tissue, skin cells or tissue, kidney or tissue, etc. In a preferred embodiment, examples of cells, tissues, or organs derived from (differentiated from) iPS cells or ES cells include nerve cells or tissue, cardiac muscle cells or tissue, cartilage cells or tissue, and skin cells or tissue.
[0077] The medical composition of the present disclosure can be used by directly administering it to a patient, or by contacting PBMCs collected from a patient in whom immune tolerance is to be induced ex vivo with the antigen for which immune tolerance is to be induced, thereby generating immune cells that are anergic against the antigen.
[0078] When the medical composition of the present disclosure is administered directly to a patient, any oral or parenteral preparation may be used. Examples of compositions for parenteral administration include eye drops, injections, nasal drops, suppositories, patches, ointments, etc. Preferably, it is an injection. Examples of the dosage form of the medical composition of the present disclosure include liquids or freeze-dried preparations. When the medical composition of the present disclosure is used as an injection, additives such as dissolution aids such as propylene glycol and ethylenediamine, buffers such as phosphates, isotonicity agents such as sodium chloride and glycerin, stabilizers such as sulfites, preservatives such as phenol, and pain-relieving agents such as lidocaine (see "Dictionary of Pharmaceutical Additives" Yakuji Nipposha, "Handbook of Pharmaceutical Excipients Fifth Edition" APhA Publications) can be added as necessary. In addition, when the medical composition of the present disclosure is used as an injection, examples of storage containers include ampoules, vials, prefilled syringes, cartridges for pen-type syringes, and drip bags.
[0079] For example, the medical composition (therapeutic or prophylactic agent) of the present disclosure can be used as an injection, and includes dosage forms such as intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection, intravitreal injection, and drip injection. Such an injection can be prepared according to a known method, for example, by dissolving, suspending, or emulsifying the above-mentioned antibody in a sterile aqueous or oily liquid that is usually used for injections. As the aqueous liquid for injection, for example, isotonic liquid containing physiological saline, glucose, sucrose, mannitol, and other adjuvants can be used, and can be used in combination with an appropriate dissolution aid, for example, alcohol (e.g., ethanol), polyalcohol (e.g., propylene glycol, polyethylene glycol), nonionic surfactant (e.g., polysorbate 80, polysorbate 20, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)), etc. As the oily liquid, for example, sesame oil, soybean oil, etc. can be used in combination with benzyl benzoate, benzyl alcohol, etc. as a dissolution aid. The prepared injection solution is usually filled into a suitable ampule, vial, or syringe. In addition, a freeze-dried preparation can be prepared by adding a suitable excipient to the antibody or its immunoreactive fragment of the present disclosure, and when used, the freeze-dried preparation can be dissolved in water for injection, physiological saline, or the like to prepare an injection solution. In general, oral administration of proteins such as antibodies is difficult because they are decomposed by the digestive tract, but oral administration is possible by ingenuity in the dosage form of antibody fragments or modified antibody fragments. Examples of preparations for oral administration include capsules, tablets, syrups, granules, and the like.
[0080] The medical composition of the present disclosure is preferably prepared in a dosage unit form suitable for the dosage of the active ingredient. Examples of such dosage unit forms include injections (ampoules, vials, prefilled syringes), which may contain 5 to 500 mg, 5 to 100 mg, or 10 to 250 mg of the antibody or immunoreactive fragment thereof of the present disclosure per dosage unit form.
[0081] The medical composition of the present disclosure may be administered locally or systemically. There is no particular limitation on the administration method, and the composition may be administered parenterally or orally as described above. Examples of parenteral administration routes include intraocular, subcutaneous, intraperitoneal, injection or drip into blood (intravenous or intraarterial), or spinal fluid, and administration into blood is preferred. The medical composition of the present disclosure (therapeutic or prophylactic agent) may be administered temporarily, or may be administered continuously or intermittently. For example, the composition may be administered continuously for 1 minute to 2 weeks.
[0082] The dosage of the medical composition of the present disclosure is not particularly limited as long as it is a dosage that can obtain a desired therapeutic or preventive effect, and can be appropriately determined depending on symptoms, sex, age, etc. The dosage of the medical composition of the present disclosure can be determined, for example, using the degree of induction of immune tolerance as an index. For example, it is convenient to administer a single dose of the active ingredient of the medical composition of the present disclosure, usually about 0.01 to 20 mg / kg body weight, preferably about 0.1 to 10 mg / kg body weight, more preferably about 0.1 to 5 mg / kg body weight, about 1 to 10 times a month, preferably about 1 to 5 times a month, by intravenous injection. In the case of other parenteral administration or oral administration, a similar amount can be administered. When the symptoms are particularly severe, the amount or frequency of administration may be increased according to the symptoms.
[0083] When the medical composition of the present disclosure is used by contacting PBMCs collected from a patient in whom immune tolerance is to be induced ex vivo with the antigen for which immune tolerance is to be induced, thereby generating immune cells that are anergic to the antigen, the composition can be prepared in the form of a liquid, powder, tablet, gel, granule, etc., similar to the composition for administration described above.
[0084] (immune tolerance-inducing cells) In another aspect, the present disclosure provides a cell in which immune tolerance is induced with the antibody described herein. The immune tolerance can be induced by mixing cells derived from a subject with an antigen or antigen content not derived from the subject. In a further aspect of the present disclosure, the present disclosure provides a method for producing cells for treating or preventing a disease, disorder or condition caused by an antigen not derived from a subject, comprising mixing an antibody described herein, cells derived from a subject, and an antigen or antigen content not derived from the subject (e.g., cells). The disease, disorder or condition can be selected from the group consisting of transplant immune rejection, allergy, autoimmune disease, graft-versus-host disease, and immune rejection caused by transplantation of iPS cells or ES cells and cells, tissues or organs derived from those cells.
[0085] In an embodiment in which the disease or the like targeted by the present disclosure is transplant immune rejection, anergy cells can be induced by mixing the above-mentioned antibody, recipient-derived cells (PBMCs or spleen cells), and donor-derived antigens or donor-derived antigen-containing material, which can be PBMCs, spleen cells, or cells from the organ to be transplanted.
[0086] In an embodiment in which the disease etc. addressed by the present disclosure is allergy, anergy cells can be induced by mixing the above-mentioned antibody, cells derived from the subject (PBMCs or spleen cells), and an antigen not derived from the subject that causes the allergy.
[0087] In an embodiment in which the disease etc. addressed by the present disclosure is an autoimmune disease, anergy cells can be induced by mixing the above-mentioned antibody, cells derived from the subject (PBMCs or spleen cells), and an antigen derived from the subject that causes the autoimmune disease.
[0088] In an embodiment in which the disease or the like targeted by the present disclosure is graft-versus-host disease, anergy cells can be induced by mixing the above-mentioned antibody, PBMCs or spleen cells of the donor providing the graft, and antigens or antigen-containing materials derived from the recipient. The antigen-containing materials derived from the recipient can be PBMCs, spleen cells, or cells in the vicinity of the site where the organ is transplanted or cells derived therefrom.
[0089] In an embodiment in which the disease etc. addressed by the present disclosure is an immune rejection reaction caused by transplantation of iPS cells or ES cells and cells, tissues or organs derived from those cells, anergy cells can be induced by mixing the above-mentioned antibody, cells derived from the subject (PBMCs or spleen cells), and cells to be used for transplantation that have been differentiated from iPS cells or ES cells.
[0090] Examples of treatment of diseases and the like according to the present disclosure are given below, but are not limited to the following.
[0091] (Allergies and autoimmune diseases) For allergies and autoimmune diseases, macrophages obtained from the peripheral blood of a patient are differentiated into dendritic cells (macrophage-derived dendritic cells) with high antigen-presenting ability by conventional methods, and these cells are made to present the antigen causing the overreaction in allergies and autoimmune diseases after irradiation (gamma rays), and are co-cultured with a group of T cells obtained from the peripheral blood of the same patient in the presence of anti-CD80 antibodies and / or anti-CD86 antibodies for 1 to 2 weeks to obtain anergy cells specific to the antigen causing the allergy or autoimmune disease. By administering these anergy cells to the patient, immune tolerance specific to the antigen causing the allergy or autoimmune disease is induced, and they are used for the prevention and treatment of allergies and autoimmune diseases. The number of administrations may be multiple times depending on various conditions such as whether it is a preventive or treatment therapy and the strength of the symptoms.
[0092] (Graft-versus-host disease) In contrast to the treatment of transplant immune rejection, in the treatment of graft-versus-host disease, cells that can cause graft-versus-host disease, such as PBMCs or T cells from the donor who provides the graft, are co-cultured with PBMCs or other cells from a host that has been irradiated (gamma rays) in the presence of anti-CD80 and / or anti-CD86 antibodies for 1 to 2 weeks to obtain host-specific anergy cells. By administering these anergy cells to the host, the reaction of the graft that causes graft-versus-host disease to the host is suppressed (immune tolerance is induced), and graft-versus-host disease is prevented and treated. The number of administrations may be multiple, depending on various conditions such as whether it is a preventive or treatment therapy, the tissue to be transplanted, its size, and the severity of symptoms.
[0093] (Immune rejection caused by transplantation of iPS cells or ES cells and cells, tissues, or organs derived from those cells) In the application of iPS cells or ES cells to therapy, the cells or dendritic cells differentiated from iPS cells or ES cells to be used for transplantation are irradiated with radiation (gamma rays), and these cells are co-cultured with the PBMC or T cell group of the patient receiving the transplantation in the presence of anti-CD80 antibody and / or anti-CD86 antibody for 1 to 2 weeks to obtain anergy cells specific to the cells differentiated from iPS cells or ES cells. These anergy cells are administered to the host to induce immune tolerance specific to the transplanted cells, tissues, and organs derived from iPS cells or ES cells, and to prevent and treat rejection of these. The number of administrations may be multiple depending on the conditions of whether it is a preventive or therapeutic therapy, the tissue to be transplanted, its size, and the severity of the symptoms.
[0094] In a specific embodiment, the present disclosure relates to a method for inducing anergy in a patient's PBMC against an antigen, comprising contacting the above-mentioned antibody (including a composition containing the above-mentioned antibody, the same applies below) with an antigen to which immune tolerance is to be induced or cells having the antigen on their surface with PBMC. The method for inducing immune tolerance of the present disclosure is performed ex vivo. For example, in organ transplantation, when the purpose is to suppress rejection of a transplanted organ in a patient, the PBMC is a cell collected from the patient. In addition, when the purpose of the PBMC is to treat or improve an autoimmune disease or allergic disease, the PBMC is a cell collected from the patient.
[0095] For example, immune tolerance to suppress rejection of organ transplants can be induced by the following method. PBMCs of a patient (recipient) receiving an organ transplant and PBMCs of a subject (donor) providing the organ are prepared, and the donor PBMCs are irradiated with 30 Gy of radiation. The donor PBMCs are mixed with the recipient PBMCs in a 1:1 ratio, and the antibody of the present disclosure (preferably a combination of anti-human CD80 antibody and anti-human CD86 antibody) is added. The recipient PBMCs are cultured in a PBMC medium at 37°C in a 5% CO2 incubator for 3 to 7 days, whereby recipient PBMCs that are anergic to the donor can be prepared.
[0096] Furthermore, for example, immune tolerance induction for treating or improving an autoimmune disease or allergic disease can be performed by the following method: Patient PBMCs are prepared, mixed with an antigen causing an autoimmune disease or allergic disease, and an antibody of the present disclosure (preferably a combination of anti-human CD80 antibody and anti-human CD86 antibody) is added. Recipient PBMCs anergic to the antigen can be prepared by culturing in a PBMC medium at 37°C in a 5% CO2 incubator for 3 to 7 days.
[0097] The present disclosure includes cells (e.g., PBMCs) in which anergy has been induced by the above method. Since the cells (e.g., PBMCs) in which anergy has been induced can induce immune tolerance in a patient by administering them to the patient, the cells (e.g., PBMCs) in which anergy has been induced can be used as a cell therapy. Thus, the present disclosure relates to a cell therapy that contains as an active ingredient the cells (e.g., PBMCs) in which anergy has been induced by the above method, preferably a cell therapy for suppressing rejection in organ transplantation that contains as an active ingredient the cells (e.g., PBMCs) of a patient receiving a transplant in which anergy has been induced against a transplanted organ, or a cell therapy for treating an autoimmune disease or an allergic disease that contains as an active ingredient the cells (e.g., PBMCs) in which anergy has been induced against an antigen that causes an autoimmune disease or an allergic disease by excessive immune reaction, and a cell therapy for suppressing rejection in transplantation of iPS cells, ES cells, or cells, tissues, or organs derived from these cells. An example of such a rejection reaction is graft-versus-host disease.
[0098] The cell therapy agent of the present disclosure can induce immune tolerance in a patient by administering it to the patient. For example, the present disclosure includes a method for suppressing rejection in an organ transplant, comprising administering to a patient receiving an organ transplant a cell therapy agent for suppressing rejection in an organ transplant, the cell therapy agent containing as an active ingredient cells (e.g., PBMCs) of the patient receiving the transplant in which anergy against the transplanted organ has been induced. The present disclosure also includes a method for treating an autoimmune disease or an allergic disease, comprising administering to a patient with the autoimmune disease or allergic disease a cell therapy agent for treating the autoimmune disease or allergic disease, the cell therapy containing as an active ingredient cells (e.g., PBMCs) in which anergy against an antigen that causes the autoimmune disease or allergic disease by excessive immune reaction. The present disclosure also includes a method for suppressing rejection reactions in the transplantation of iPS cells or ES cells, or cells, tissues or organs derived from those cells, comprising administering to a patient receiving an organ transplant a cell therapy for suppressing rejection reactions in the transplantation of iPS cells or ES cells, or cells, tissues or organs derived from those cells, which contains as an active ingredient cells of the patient receiving the transplant (e.g., PBMCs) in which anergy has been induced in the iPS cells or ES cells to be transplanted, or cells, tissues or organs derived from those cells.
[0099] The cell therapy agent of the present disclosure contains PBMCs in a serum-containing / non-containing medium or physiological saline that can be administered to humans. If the cells are adhesive, they can be stored on a substrate that allows cells to be detached, and the cells can be detached when needed. For example, a substrate that allows cells to be detached by temperature change (RepCell, CellSeed, Japan) can be used.
[0100] The present disclosure may be a method for inducing immune tolerance in a patient, comprising inducing anergy in a patient's cells (e.g., PBMCs) against an antigen to which immune tolerance is to be induced by contacting the antibody with the antigen or cells having the antigen on their surface, and administering the anergy-induced cells (e.g., PBMCs) to the patient. For example, the present disclosure includes a method for suppressing rejection in organ transplantation, comprising inducing anergy in the patient's cells (e.g., PBMCs) against a transplanted organ by contacting donor-derived cells with the patient's cells (e.g., PBMCs), thereby preparing patient-derived cells (e.g., PBMCs) in which immune tolerance to the transplanted organ has been induced, and administering the prepared cells (e.g., PBMCs) to a patient receiving an organ transplant. The present disclosure may also be a method for treating or ameliorating an autoimmune disease or allergic disease, comprising: preparing patient-derived cells (e.g., PBMCs) in which immune tolerance to the antigen that causes the autoimmune disease or allergic disease has been induced by contacting the patient's cells (e.g., PBMCs) with an antigen that causes the autoimmune disease or allergic disease, thereby inducing anergy in the patient's cells (e.g., PBMCs) against the antigen, and administering the prepared cells (e.g., PBMCs) to a patient with the autoimmune disease or allergic disease. The present disclosure also includes a method for suppressing rejection in transplantation of iPS cells or ES cells, or cells, tissues or organs derived from these cells, comprising: preparing patient-derived cells (e.g., PBMCs) in which immune tolerance has been induced to the iPS cells or ES cells, or cells, tissues or organs derived from these cells, by contacting iPS cells or ES cells, or cells, tissues or organs derived from these cells, with patient's cells (e.g., PBMCs) to induce anergy in the patient's cells (e.g., PBMCs) toward the iPS cells or ES cells, or cells, tissues or organs derived from these cells, and administering the prepared cells (e.g., PBMCs) to a patient receiving a transplant of iPS cells or ES cells, or cells, tissues or organs derived from these cells.
[0101] Herein, the administration of a cell therapy agent (cells in which anergy has been induced, such as PBMCs) is not particularly limited as long as the desired therapeutic or preventive effect is obtained, and can be appropriately determined depending on symptoms, sex, age, and the like. The dose of the cell therapy agent of the present disclosure can be determined, for example, using the degree of induction of immune tolerance as an index. For example, a single dose of anergy-induced PBMCs of the cell therapy agent of the present disclosure is usually 1.0 to 3.7 × 10 7 Approximately 2.0 to 5.0 × 10 cells / kg body weight, preferably 2.0 to 5.0 × 10 7 Approximately 3.0 to 5.0 × 10 cells / kg body weight, more preferably 3.0 to 5.0 × 10 7 It is convenient to administer cells / kg body weight by intravenous injection about 1 to 10 times a month, preferably about 1 to 5 times a month. If no immunosuppressive effect is observed, the amount or frequency of administration may be increased depending on the symptoms.
[0102] (Note) In this specification, "or" is used when "at least one or more" of the items listed in the sentence can be employed. The same applies to "alternative." In this specification, when it is specified that "within a range of two values," the range includes the two values themselves.
[0103] All references cited herein, including scientific literature, patents, patent applications, and the like, are hereby incorporated by reference in their entirety to the same extent as if each was specifically set forth.
[0104] The present disclosure has been described above by showing preferred embodiments for ease of understanding. The present disclosure will be described below based on examples, but the above description and the following examples are provided for illustrative purposes only and are not provided for the purpose of limiting the present disclosure. Therefore, the scope of the present disclosure is not limited to the embodiments or examples specifically described in this specification, but is limited only by the scope of the claims. EXAMPLES
[0105] The present disclosure will be described in more detail below with reference to examples. However, the present disclosure is not limited to these examples. All documents cited throughout this application are incorporated by reference in their entirety.
[0106] Examples are described below. The handling of the organisms used in the following examples complied with the standards stipulated by Juntendo University and the supervisory authorities. Animal experiments were conducted in compliance with the Juntendo University Animal Experiment Management Regulations established based on the "Law Concerning the Protection and Management of Animals," "Standards for the Care and Storage of Laboratory Animals and the Relief of Pain" (Ministry of the Environment Notification No. 88, 2006), and "Basic Guidelines for the Conduct of Animal Experiments, etc. in Research Institutions" (Ministry of Education, Culture, Sports, Science and Technology Notification No. 71, 2006). The experiments were planned based on the so-called 3Rs, and the plan was submitted to the Juntendo University School of Medicine Experimental Animal Committee, which reviewed the plan and has already been approved and accepted. Regarding the use of genetically engineered mice, the experimental plan using recombinant DNA-produced animals was reviewed and approved by the university safety committee. Furthermore, regarding recombinant DNA experiments, the plan was submitted to the Juntendo University School of Medicine DNA Experiment Safety Committee, which reviewed the plan and has already been approved and accepted, and the research was conducted in accordance with the relevant provisions of the "Law Concerning the Conservation of Biological Diversity through Regulations on the Use of Genetically Modified Organisms, etc." The experiments using human peripheral blood (PBMC) have already been approved by the Juntendo University School of Medicine Ethics Committee, which has reviewed the experiment based on the principles of fair deliberation and information disclosure and deemed it appropriate. After obtaining informed consent from the sample donors regarding the research purpose, plan, and method, the research was carried out while strictly protecting personal information and maintaining anonymity. In carrying out the experiments, we complied with the ethical regulations established by the Juntendo University School of Medicine and Sagamihara Hospital Ethics Committee, as well as the "Guidelines for Clinical Research" established by the Ministry of Health, Labor, and Welfare. The specific reagents used are those listed in the examples, but equivalent products from other manufacturers (Sigma-Aldric, Wako Pure Chemical Industries, Nakarai, R&D Systems, USCN Life Science INC, BD bioscience, BioLegend, etc.) can also be used.
[0107] (Example 1) Mixed lymphocyte reaction (MLR) in the presence of anti-human CD80 and anti-CD86 antibodies (subclass IgG1) (material and method) Mononuclear cells (PBMCs) were isolated from the peripheral blood of three volunteers (one donor (Donor C) and two recipients (Recipient A and Recipient B)) using Promo Cell's Lymphocyte Separation Media (Cat. No. C-44010). They were cultured at 4 × 10 6 The donor PBMCs were irradiated with γ-rays at a dose of 30 Gy.
[0108] Donor PBMCs and recipient PBMCs were dispensed into 4 wells of a 96-well plate (Corning, Cat. No. 3799) at 100 μL / well (final total of 200 μL / well) so that the ratio was 1:1. 10 μL of a combination of humanized anti-human CD80 antibody (v2 (subclass IgG1)) and anti-human CD86 antibody (v5 (subclass IgG1)), or a combination of mouse anti-human CD80 antibody (Cat. No. 16-0809-85) (subclass IgG1) and mouse anti-human CD86 antibody (Cat. No. 16-0869-85) (subclass IgG2) manufactured by eBioscience was added at 10 μL each so that the post-addition concentrations of each antibody were 0.1, 1, and 10 μg / mL, and culture was started in a 37°C, 5% CO2 incubator. On the fourth day after the start of culture, 3 H-thymidine (10 μL) was added, and the 5th day ( 3 16-20 hours after the addition of H-thymidine, the cultured cells were harvested using a Cell Harvester (Molecular Devices) and counted in a scintillation counter. 3 H-thymidine incorporation was measured.
[0109] IFNγ production was measured by mixing PBMCs in the same manner as described above and adding each antibody in the same manner, dispensing 500 μL / well into 3 wells of a 48-well plate (Corning, Cat. No. 3548), and incubating at 37°C in a 5% CO2 incubator. On the 6th day of culture, the supernatant was collected, and the collected sample was diluted 10-25 times and then analyzed using Bioligands Human IFNγ ELISA MAX. TM Measurements were performed using Deluxe, Cat. 430104.
[0110] (result) As a result, as shown in Figure 1, the combination of humanized anti-human CD80 antibody (v2 (subclass IgG1)) and humanized anti-human CD86 antibody (v5 (subclass IgG1)) showed almost the same activity as the combination of mouse anti-human CD80 antibody and mouse anti-human CD86 antibody manufactured by eBioscience. 3 H-thymidine incorporation was low, i.e., activation of immune cells was suppressed. On the other hand, as shown in FIG. 2, the results of IFNγ production evaluation showed that while production was low in the presence of eBioscience's mouse anti-human CD80 and CD86 antibodies, IFNγ production was observed depending on the amount of antibody added in the presence of humanized anti-human CD80 and CD86 antibodies (subclass IgG1), and at 10 μg / mL, production was greater than that in the absence of the antibody (Figure 2 Allo). Although we do not wish to be bound by theory, it is believed that the eBioscience antibody produces less IFNγ due to its low reactivity as a mouse antibody.
[0111] (Example 2) Mixed lymphocyte reaction (MLR) in the presence of anti-human CD80 and anti-CD86 antibodies (subclass IgG1) (material and method) In the same manner as in Example 1, a combination of humanized anti-human CD80 antibody (v2 (subclass IgG1)) and anti-human CD86 antibody (v5 or v9 (subclass IgG1)), or a combination of mouse anti-human CD80 antibody (Cat. No. 16-0809-85) and mouse anti-human CD86 antibody (Cat. No. 16-0869-85) manufactured by eBioscience was added so that the concentration of each antibody after addition was 10 μg / mL. 3 H-thymidine incorporation was evaluated. Of the three volunteers, one was designated as a donor (Donor F) and two were designated as recipients (Recipients D and E).
[0112] Furthermore, IFNγ production was evaluated for a combination of humanized anti-human CD80 antibody (v2 (subclass IgG1)) and humanized anti-human CD86 antibody (v9 (subclass IgG1)), and a combination of mouse anti-human CD80 antibody and anti-human CD86 antibody manufactured by eBioscience. In addition to the method of Example 1, the combination of humanized anti-human CD80 antibody (v2 (subclass IgG1)) and anti-human CD86 antibody (v9 (subclass IgG1)) was also evaluated for IFNγ production in the absence of irradiated donor PBMC.
[0113] (result) As a result, as shown in Figure 3, the combination of humanized anti-human CD80 antibody and anti-human CD86 antibody was more effective than the combination of mouse anti-human CD80 antibody and anti-human CD86 antibody. 3 4, IFNγ production was low with the mouse anti-human CD80 and CD86 antibodies manufactured by eBioscience, as in Example 1. With the humanized anti-human CD80 and CD86 antibodies, production was equal to or greater than that observed with donor stimulation in the absence of antibodies, and even in the absence of irradiated donor PBMC, similar IFNγ production was observed when humanized anti-CD80 and anti-human CD86 antibodies were added.
[0114] (Example 3) Mixed lymphocyte reaction (MLR) in the presence of anti-human CD80 and anti-CD86 antibodies (subclasses IgG1, IgG2, IgG4) In Example 2, since IFNγ production was observed even without adding irradiated donor PBMC, class switching of humanized anti-human CD80 antibody and anti-human CD86 antibody was performed, and a combination of the same subclass of this humanized anti-human CD80 antibody (v2 (subclass IgG2 or IgG4)) and anti-human CD86 antibody (v9 (subclass IgG2 or IgG4)), as well as a combination of mouse anti-human CD80 antibody (product number 16-0809-85) and anti-human CD86 antibody (product number 16-0869-85) manufactured by eBioscience were added so that the concentration of each antibody after addition was 1, 3, or 10 μg / mL. 3 H-thymidine incorporation and IFNγ production were evaluated when each antibody was added to a post-addition concentration of 10 μg / mL. Of the three volunteers, one was designated as a donor (donor I) and two were designated as recipients (recipient G and recipient H). The specific experimental system was as follows.
[0115] [ 3 H-thymidine incorporation (antibody concentrations 1, 3, and 10 μg / mL each) (Figure 5) -No antibody added (Allo), irradiated donor PBMC added - eBioscience Mouse anti-human CD80 antibody, Mouse anti-human CD86 antibody -Humanized anti-human CD80 antibody (v2 (IgG2)), humanized anti-human CD86 antibody (v9 (IgG2)) -Humanized anti-human CD80 antibody (v2(IgG4)), humanized anti-human CD86 antibody (v9(IgG4))
[0116] [IFNγ production (antibody concentration 10 μg / mL each)] (Figure 6) Irradiated donor PBMCs added (Allo) -No antibody added - eBioscience Mouse anti-human CD80 antibody, anti-human CD86 antibody -Humanized anti-human CD80 antibody (v2 (IgG2)), humanized anti-human CD86 antibody (v9 (IgG2)) -Humanized anti-human CD80 antibody (v2(IgG4)), humanized anti-human CD86 antibody (v9(IgG4)) No addition of irradiated donor PBMCs (Naive) -No antibody added - eBioscience Mouse CD80 antibody, anti-CD86 antibody -Humanized anti-CD80 antibody (v2(IgG1)), humanized anti-human CD86 antibody (v9(IgG1)) -Humanized anti-CD80 antibody (v2(IgG2)), humanized anti-human CD86 antibody (v9(IgG2)) -Humanized anti-CD80 antibody (v2(IgG4)), humanized anti-human CD86 antibody (v9(IgG4))
[0117] (result) As a result, as shown in FIG. 5, the subclasses IgG2 and IgG4 were similar to those in Examples 1 and 2. 3 On the other hand, as shown in Figure 6, IFNγ production was observed in the IgG1 subclass, but surprisingly, no IFNγ was produced in the IgG2 and IgG4 subclasses.
[0118] (Example 4) Mixed lymphocyte reaction (MLR) when cells cultured in the presence of anti-human CD80 and anti-human CD86 antibodies (subclasses IgG1, IgG2, and IgG4) were added (material and method) Using the method described in Example 1, the culture was continued until day 14 in the presence of a combination of humanized anti-human CD80 antibody (v2) and anti-human CD86 antibody (v9) of subclasses IgG1, IgG2, and IgG4. The humanized anti-human CD80 antibody (v2) of subclass IgG2 has a heavy chain consisting of the amino acid sequence of SEQ ID NO: 2, and a light chain consisting of the amino acid sequence of SEQ ID NO: 4. The humanized anti-human CD80 antibody (v2) of subclass IgG4 has a heavy chain consisting of the amino acid sequence of SEQ ID NO: 6, and a light chain consisting of the amino acid sequence of SEQ ID NO: 8. The anti-human CD86 antibody (v9) of subclass IgG2 has a heavy chain consisting of the amino acid sequence of SEQ ID NO: 10, and a light chain consisting of the amino acid sequence of SEQ ID NO: 12. The anti-human CD86 antibody (v9) of subclass IgG4 has a heavy chain consisting of the amino acid sequence of SEQ ID NO: 14, and a light chain consisting of the amino acid sequence of SEQ ID NO: 16. After the culture, the obtained anergy cells were mixed with recipient PBMCs (R-PBMCs) and irradiated donor PBMCs (D-PBMCs) according to the table below, and then cultured by the method described in Example 1. 3 H-thymidine incorporation was assessed.
[0119] [Table 1]
[0120] (result) As a result, as shown in FIG. 7, the cells obtained in the presence of antibodies of any subclass showed similar cell proliferation. 3 3H-thymidine incorporation was inhibited.
[0121] Example 5: Induction of immune tolerance in organ transplant patients The test was performed using a method similar to that described in Satoru Todo et al. Hepatorogy, 64(vol.2), 632-643 (2016). Briefly, lymphocytes collected from the recipient's spleen or peripheral blood, lymphocytes from a donor irradiated with 30 Gy, and the humanized anti-CD80 antibody and anti-CD86 antibody of subclass IgG4 used in Example 4 are co-cultured to induce anergy T cells specific to donor antigens. The anergy T cells are administered to the recipient who received a liver transplant on the 13th day after surgery. The progress is then observed.
[0122] Example 6: Chimeric anti-human CD80 and chimeric anti-human CD86 antibodies (subclass IgG1) Antibody production The present inventors attempted to improve anti-human CD80 and anti-human CD86 antibodies in consideration of their use in cell therapy. Specifically, chimeric antibodies were produced based on mouse anti-human CD80 and mouse anti-human CD86 antibodies manufactured by eBioscience. The chimeric anti-human CD80 antibody (subclass IgG1) produced had a heavy chain consisting of the amino acid sequence of SEQ ID NO: 38 and a light chain consisting of the amino acid sequence of SEQ ID NO: 40. The chimeric anti-human CD86 antibody (subclass IgG1) produced had a heavy chain consisting of the amino acid sequence of SEQ ID NO: 42 and a light chain consisting of the amino acid sequence of SEQ ID NO: 44. Plasmids encoding these were commissioned to an external company (TPG Biologics, Inc., Taiwan) to be expressed in CHO cells, and the antibodies were produced and purified.
[0123] Mixed lymphocyte reaction (MLR) in the presence of chimeric anti-human CD80 and chimeric anti-CD86 antibodies (subclass IgG1) IFNγ production In a manner similar to that described in Example 1, mononuclear cells (PBMCs) were isolated from the human peripheral blood of two volunteers (one designated as the donor and the other as the recipient) using Lymphocyte Separation Media (Cat. No. C-44010) manufactured by Promo Cell, and cultured at 2 × 10 6 The donor PBMCs were irradiated with γ-rays at 30 Gy.
[0124] The experimental system was constructed as follows: 1. "Naive": 1 × 10 recipient PBMC 6 cell 2. "Allo": 1 × 10 recipient PBMC 6 Cells and donor PBMCs 1 x 10 6 cell 3. "Chimeric anti-CD80": 1 x 10 recipient PBMC 6 Cells and chimeric anti-human CD80 antibody 4μg 4. "Chimeric anti-CD86": 1 x 10 recipient PBMC 6 Cells and chimeric anti-human CD86 antibody 4μg Series 1 to 4 were placed in each well of a 96-well plate (Corning, Cat. No. 3799) to give a final reaction volume of 200 μL (final antibody concentration was approximately 20 μg / mL). Culture was started in a 37°C, 5% CO2 incubator. The supernatant was collected on the 5th and 6th days after the start of culture, and the collected samples were diluted 20 to 25 times and then analyzed using Bioligands Human IFNγ ELISA MAX. TM Measurements were performed using Deluxe, Cat. 430104.
[0125] result As shown in FIG. 8, neither the chimeric anti-human CD80 nor the chimeric anti-human CD86 antibodies induced detectable IFNγ production.
[0126] 3H-thymidine incorporation assay Basically, the experiments were carried out according to the methods described in Examples 1 and 4. Recipient PBMCs and donor PBMCs were either freshly isolated from human peripheral blood or rapidly thawed after being frozen and stored at -80°C. Both of these cells were cultured at 4 × 10 in ALyS505N-0 medium (Cell Science Institute (CSTI) 1020P10) containing 2% human serum type AB (pooled) manufactured by Biowest. 6 The donor PBMCs were irradiated with 20 Gy radiation. The recipient PBMCs and donor PBMCs were mixed at a 1:1 ratio, and chimeric anti-human CD80 antibody and chimeric anti-human CD86 antibody were added to the mixture at a final concentration of 10 μg / ml. The cells were cultured in 6-10 cm petri dishes (culture volume 6-18 mL) at 37°C in a 5% CO2 incubator for 7 days.
[0127] On day 7 after the start of culture, the cultured recipient PBMCs were collected by centrifugation and resuspended in the above medium at 4 × 10 6 Freshly prepared irradiated donor PBMCs were added to the cultured recipient PBMCs at a cell ratio of 2:1, and chimeric anti-human CD80 antibody and chimeric anti-human CD86 antibody were added at a final concentration of 5 μg / ml. The culture was carried out under the same conditions as above for 7 days (cell density: 4 × 10 6 cells / mL).
[0128] On the 14th day after the start of culture, the induced cells are harvested by centrifugation and mixed in the following ratio: 1. "Naive": 4 × 10 recipient PBMCs 5 cell 2. "allo": recipient PBMC 4 × 10 5 Cells and donor PBMCs 4 x 10 5 cell 3. "1:1 / 2": Recipient PBMC 4 × 10 5 Cells and donor PBMCs 4 x 10 5 Cells and derived cells 2×10 5cell 4. "1:1 / 4": 4 × 10 recipient PBMCs 5 Cells and donor PBMCs 4 x 10 5 Cells and derived cells 1×10 5 cell 5. "1:1 / 8": Recipient PBMC 4 × 10 5 Cells and donor PBMCs 4 x 10 5 Cells and derived cells 5×10 4 cell 6. "1:1 / 16": Recipient PBMC 4 × 10 5 Cells and donor PBMCs 4 x 10 5 Cells and induced cells 2.5×10 4 cell Each of the lines 1 to 6 was dispensed into 4 wells of a 96-well plate (Corning, Cat. No. 3799) and co-cultured at 37°C in a 5% CO2 incubator. 3 H-thymidine (10 μl) was added, and the 5th day after the start of co-culture ( 3 16-20 hours after the addition of H-thymidine 3 Removes H-thymidine, 3 H-thymidine incorporation was measured.
[0129] result As shown in FIG. 9, the induced cells were dose-dependently 3 The amount of H-thymidine incorporation was reduced (i.e., the activation of immune cells was suppressed). Therefore, it was demonstrated that the chimeric anti-human CD80 antibody and the chimeric anti-human CD86 antibody are suitable for cell therapy because they can induce anergic T cells and do not cause harmful IFNγ production.
[0130] (Note) As described above, the present disclosure has been illustrated using preferred embodiments of the present disclosure, but it is understood that the scope of the present disclosure should be interpreted only by the claims. It is understood that the patents, patent applications, and other documents cited in this specification should be incorporated by reference to this specification in the same manner as if the contents themselves were specifically described in this specification. This application claims the benefit of priority to Japanese Patent Application No. 2018-118996 (filed June 22, 2018), and it is understood that the contents of the application are incorporated by reference in this application (which may be in whole). In addition, the contents of Japanese Patent Application No. 2018-119001 and Japanese Patent Application No. 2018-1190031 (both filed June 22, 2018) and international applications claiming priority thereto are incorporated by reference in part or in whole herein. [Industrial Applicability]
[0131] The present disclosure provides an antibody having a structure with characteristics that improve the effect of immune tolerance or do not attenuate the effect of immune tolerance. The present disclosure provides a technology that can be used in the pharmaceutical industry related to formulations based on such technology. [Sequence List Free Text]
[0132] SEQ ID NO: 1: Anti-CD80 antibody (IgG2) heavy chain nucleic acid sequence SEQ ID NO: 2: Anti-CD80 antibody (IgG2) heavy chain amino acid sequence SEQ ID NO: 3: Anti-CD80 antibody (IgG2) light chain nucleic acid sequence SEQ ID NO: 4: Anti-CD80 antibody (IgG2) light chain amino acid sequence SEQ ID NO: 5: Anti-CD80 antibody (IgG4) heavy chain nucleic acid sequence SEQ ID NO: 6: Anti-CD80 antibody (IgG4) heavy chain amino acid sequence SEQ ID NO: 7: Anti-CD80 antibody (IgG4) light chain nucleic acid sequence SEQ ID NO: 8: Anti-CD80 antibody (IgG4) light chain amino acid sequence SEQ ID NO: 9: Anti-CD86 antibody (IgG2) heavy chain nucleic acid sequence SEQ ID NO: 10: Anti-CD86 antibody (IgG2) heavy chain amino acid sequence SEQ ID NO: 11: Anti-CD86 antibody (IgG2) light chain nucleic acid sequence SEQ ID NO: 12: Anti-CD86 antibody (IgG2) light chain amino acid sequence SEQ ID NO: 13: Anti-CD86 antibody (IgG4) heavy chain nucleic acid sequence SEQ ID NO: 14: Anti-CD86 antibody (IgG4) heavy chain amino acid sequence SEQ ID NO: 15: Anti-CD86 antibody (IgG4) light chain nucleic acid sequence SEQ ID NO: 16: Anti-CD86 antibody (IgG4) light chain amino acid sequence SEQ ID NO: 17: Anti-CD80 antibody (IgG2) heavy chain variable region nucleic acid sequence SEQ ID NO: 18: Anti-CD80 antibody (IgG2) heavy chain variable region amino acid sequence SEQ ID NO: 19: Anti-CD80 antibody (IgG2) light chain variable region nucleic acid sequence SEQ ID NO: 20: Anti-CD80 antibody (IgG2) light chain variable region amino acid sequence SEQ ID NO: 21: Anti-CD86 antibody (IgG2) heavy chain variable region nucleic acid sequence SEQ ID NO: 22: Anti-CD86 antibody (IgG2) heavy chain variable region amino acid sequence SEQ ID NO: 23: Anti-CD86 antibody (IgG2) light chain variable region nucleic acid sequence SEQ ID NO: 24: Anti-CD86 antibody (IgG2) light chain variable region amino acid sequence SEQ ID NO: 25: Anti-CD80 antibody (IgG2) CDRH1 amino acid sequence SEQ ID NO: 26: Anti-CD80 antibody (IgG2) CDRH2 amino acid sequence SEQ ID NO: 27: Anti-CD80 antibody (IgG2) CDRH3 amino acid sequence SEQ ID NO: 28: Anti-CD80 antibody (IgG2) CDRL1 amino acid sequence SEQ ID NO: 29: Anti-CD80 antibody (IgG2) CDRL2 amino acid sequence SEQ ID NO: 30: Anti-CD80 antibody (IgG2) CDRL3 amino acid sequence SEQ ID NO: 31: Anti-CD86 antibody (IgG2) CDRH1 amino acid sequence SEQ ID NO: 32: Anti-CD86 antibody (IgG2) CDRH2 amino acid sequence SEQ ID NO: 33: Anti-CD86 antibody (IgG2) CDRH3 amino acid sequence SEQ ID NO: 34: Anti-CD86 antibody (IgG2) CDRL1 amino acid sequence SEQ ID NO: 35: Anti-CD86 antibody (IgG2) CDRL2 amino acid sequence SEQ ID NO: 36: Anti-CD86 antibody (IgG2) CDRL3 amino acid sequence SEQ ID NO: 37 Chimeric anti-CD80 antibody heavy chain nucleic acid sequence SEQ ID NO: 38 Chimeric anti-CD80 antibody heavy chain amino acid sequence SEQ ID NO: 39 Chimeric anti-CD80 antibody light chain nucleic acid sequence SEQ ID NO: 40 Chimeric anti-CD80 antibody light chain amino acid sequence SEQ ID NO: 41 Chimeric anti-CD86 antibody heavy chain nucleic acid sequence SEQ ID NO: 42 Chimeric anti-CD86 antibody heavy chain amino acid sequence SEQ ID NO: 43 Chimeric anti-CD86 antibody light chain nucleic acid sequence SEQ ID NO: 44 Chimeric anti-CD86 antibody light chain amino acid sequence SEQ ID NO: 45 Chimeric anti-CD80 antibody heavy chain variable region nucleic acid sequence SEQ ID NO: 46 Chimeric anti-CD80 antibody heavy chain variable region amino acid sequence SEQ ID NO: 47 Chimeric anti-CD80 antibody light chain variable region nucleic acid sequence SEQ ID NO: 48 Chimeric anti-CD80 antibody light chain variable region amino acid sequence SEQ ID NO: 49 Chimeric anti-CD86 antibody heavy chain variable region nucleic acid sequence SEQ ID NO: 50 Chimeric anti-CD86 antibody heavy chain variable region amino acid sequence SEQ ID NO: 51 Chimeric anti-CD86 antibody light chain variable region nucleic acid sequence SEQ ID NO: 52 Chimeric anti-CD86 antibody light chain variable region amino acid sequence SEQ ID NO: 53 Chimeric anti-CD80 antibody CDRH1 amino acid sequence SEQ ID NO: 54 Chimeric anti-CD80 antibody CDRH2 amino acid sequence SEQ ID NO: 55 Chimeric anti-CD80 antibody CDRH3 amino acid sequence SEQ ID NO: 56 Chimeric anti-CD80 antibody CDRL1 amino acid sequence SEQ ID NO: 57 Chimeric anti-CD80 antibody CDRL2 amino acid sequence SEQ ID NO: 58 Chimeric anti-CD80 antibody CDRL3 amino acid sequence SEQ ID NO: 59 Chimeric anti-CD86 antibody CDRH1 amino acid sequence SEQ ID NO: 60 Chimeric anti-CD86 antibody CDRH2 amino acid sequence SEQ ID NO: 61 Chimeric anti-CD86 antibody CDRH3 amino acid sequence SEQ ID NO: 62 Chimeric anti-CD86 antibody CDRL1 amino acid sequence SEQ ID NO: 63 Chimeric anti-CD86 antibody CDRL2 amino acid sequence SEQ ID NO: 64 Chimeric anti-CD86 antibody CDRL3 amino acid sequence
Claims
[Claim 1] The invention as depicted in the drawings.
Citation Information
Patent Citations
Regulatory T cells and their uses
JP2016520081A
Compositions and methods for preventing graft rejection and anti-adaptive T lymphocyte-mediated immune responses
JP2002504120A
Kidney transplantation rejection symptom inhibitor
JP2007131598A
